<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD with MathML3 v1.2 20190208//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-journalpublishing1-mathml3.dtd?>
<?SourceDTD.Version 1.2?>
<?ConverterInfo.XSLTName jats2jats3.xsl?>
<?ConverterInfo.Version 1?>
<?all-math-mml yes?>
<?use-mml?>
<?properties open_access?>
<?properties manuscript?>
<?origin nihpa?>
<?iso-abbr Eur J Cancer?>
<?submitter-system nihms?>
<?submitter-userid 2144468?>
<?submitter-authority myNCBI?>
<?submitter-login fullercd@era+commons?>
<?submitter-name Clifton Fuller?>
<?domain nihpa?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-journal-id">9005373</journal-id>
    <journal-id journal-id-type="pubmed-jr-id">1697</journal-id>
    <journal-id journal-id-type="nlm-ta">Eur J Cancer</journal-id>
    <journal-id journal-id-type="iso-abbrev">Eur J Cancer</journal-id>
    <journal-title-group>
      <journal-title>European journal of cancer (Oxford, England : 1990)</journal-title>
    </journal-title-group>
    <issn pub-type="ppub">0959-8049</issn>
    <issn pub-type="epub">1879-0852</issn>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">9853413</article-id>
    <article-id pub-id-type="pmid">36442460</article-id>
    <article-id pub-id-type="doi">10.1016/j.ejca.2022.10.011</article-id>
    <article-id pub-id-type="manuscript">nihpa1864360</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Article</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>Head and neck cancer predictive risk estimator to determine control and therapeutic outcomes of radiotherapy (HNC-PREDICTOR): development, international multi-institutional validation, and web implementation of clinic-ready model-based risk stratification for head and neck cancer</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <name>
          <surname>van Dijk</surname>
          <given-names>Lisanne V.</given-names>
        </name>
        <xref rid="A1" ref-type="aff">a</xref>
        <xref rid="A2" ref-type="aff">b</xref>
        <xref rid="CR1" ref-type="corresp">*</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Mohamed</surname>
          <given-names>Abdallah SR.</given-names>
        </name>
        <xref rid="A1" ref-type="aff">a</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Ahmed</surname>
          <given-names>Sara</given-names>
        </name>
        <xref rid="A1" ref-type="aff">a</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Nipu</surname>
          <given-names>Nafiul</given-names>
        </name>
        <xref rid="A3" ref-type="aff">c</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Marai</surname>
          <given-names>G. Elisabeta</given-names>
        </name>
        <xref rid="A3" ref-type="aff">c</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Wahid</surname>
          <given-names>Kareem</given-names>
        </name>
        <xref rid="A1" ref-type="aff">a</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Sijtsema</surname>
          <given-names>Nanna M.</given-names>
        </name>
        <xref rid="A2" ref-type="aff">b</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Gunn</surname>
          <given-names>Brandon</given-names>
        </name>
        <xref rid="A1" ref-type="aff">a</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Garden</surname>
          <given-names>Adam S.</given-names>
        </name>
        <xref rid="A1" ref-type="aff">a</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Moreno</surname>
          <given-names>Amy</given-names>
        </name>
        <xref rid="A1" ref-type="aff">a</xref>
        <xref rid="A4" ref-type="aff">d</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Hope</surname>
          <given-names>Andrew J.</given-names>
        </name>
        <xref rid="A5" ref-type="aff">e</xref>
        <xref rid="A6" ref-type="aff">f</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Langendijk</surname>
          <given-names>Johannes A.</given-names>
        </name>
        <xref rid="A2" ref-type="aff">b</xref>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Fuller</surname>
          <given-names>Clifton D.</given-names>
        </name>
        <xref rid="A1" ref-type="aff">a</xref>
        <xref rid="A4" ref-type="aff">d</xref>
      </contrib>
    </contrib-group>
    <aff id="A1"><label>a</label>Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA</aff>
    <aff id="A2"><label>b</label>Department of Radiation Oncology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands</aff>
    <aff id="A3"><label>c</label>Department of Computer Science, The University of Illinois Chicago, Chicago, USA</aff>
    <aff id="A4"><label>d</label>MD Anderson Stiefel Center for Oropharyngeal Cancer Research and Education (MDA-SCORE), Houston, TX, USA</aff>
    <aff id="A5"><label>e</label>Department of Radiation Oncology, University of Toronto, Toronto, Canada</aff>
    <aff id="A6"><label>f</label>Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada</aff>
    <author-notes>
      <fn fn-type="con" id="FN1">
        <p id="P1">Author contribution</p>
        <p id="P2"><bold>Lisanne V. van Dijk</bold>: Conceptualisation, Methodology, Investigation, Data curation and organization, Software, Formal Analysis, Web-based tool development, Writing – original draft, review and editing, Visualisation; <bold>Abdallah S R Mohamed</bold>: Conceptualisation, Methodology, Data curation and organization, tumour contouring, Writing – original draft, Visualisation; <bold>Sara Ahmed</bold>: Data curation and organization, tumour contouring, Writing – original draft; <bold>Nafiul Nipu</bold>: Web-based tool development, Writing – draft, review and editing; <bold>G. Elisabeta Marai</bold>: Web-based tool development, Writing – draft, review and editing; <bold>Kareem Wahid</bold>: Data curation and organization, Writing – draft, review and editing; <bold>Nanna M. Sijtsema</bold>: Writing – draft, review and editing; <bold>Brandon Gunn</bold>: Data curation, Writing e draft, review and editing; <bold>Adam S. Garden</bold>: Data curation, Writing – draft, review and editing, Visualisation; <bold>Amy Moreno</bold>: Data curation, Writing – draft, review and editing; <bold>Andrew J. Hope</bold>: Validation, Data curation, Writing – draft, review and editing; <bold>Johannes A. Langendijk</bold>: Conceptualisation, Methodology, Validation, Data organization, Writing – draft, review and editing, Visualisation; <bold>Clifton D. Fuller</bold>: Conceptualisation, Methodology, Investigation, Data organization, Formal analysis, Web-based tool development, Writing – draft, review and editing, Visualisation.</p>
      </fn>
      <corresp id="CR1"><label>*</label><italic toggle="yes">Corresponding author</italic>: Department of Radiation Oncology, University Medical Center Groningen, PO Box 30001, 9700 RB Groningen, the Netherlands, <email>l.v.van.dijk@umcg.nl</email> (L.V. van Dijk).</corresp>
    </author-notes>
    <pub-date pub-type="nihms-submitted">
      <day>14</day>
      <month>1</month>
      <year>2023</year>
    </pub-date>
    <pub-date pub-type="ppub">
      <month>1</month>
      <year>2023</year>
    </pub-date>
    <pub-date pub-type="epub">
      <day>21</day>
      <month>10</month>
      <year>2022</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>20</day>
      <month>1</month>
      <year>2023</year>
    </pub-date>
    <volume>178</volume>
    <fpage>150</fpage>
    <lpage>161</lpage>
    <permissions>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>This is an open access article under the CC BY license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p>
      </license>
    </permissions>
    <abstract id="ABS1">
      <sec id="S1">
        <title>Background:</title>
        <p id="P3">Personalised radiotherapy can improve treatment outcomes of patients with head and neck cancer (HNC), where currently a ‘one-dose-fits-all’ approach is the standard. The aim was to establish individualised outcome prediction based on multi-institutional international ‘big-data’ to facilitate risk-based stratification of patients with HNC.</p>
      </sec>
      <sec id="S2">
        <title>Methods:</title>
        <p id="P4">The data of 4611 HNC radiotherapy patients from three academic cancer centres were split into four cohorts: a training (n = 2241), independent test (n = 786), and external validation cohorts 1 (n = 1087) and 2 (n = 497). Tumour- and patient-related clinical variables were considered in a machine learning pipeline to predict overall survival (primary end-point) and local and regional tumour control (secondary end-points); serially, imaging features were considered for optional model improvement. Finally, patients were stratified into high-, intermediate-, and low-risk groups.</p>
      </sec>
      <sec id="S3">
        <title>Results:</title>
        <p id="P5"><italic toggle="yes">Performance score, AJCC</italic><sup><italic toggle="yes">8th</italic></sup><italic toggle="yes">stage, pack-years,</italic> and <italic toggle="yes">Age</italic> were identified as predictors for overall survival, demonstrating good performance in both the training cohort (c-index = 0.72 [95% CI, 0.66–0.77]) and in all three validation cohorts (c-indices: 0.76 [0.69–0.83], 0.73 [0.68–0.77], and 0.75 [0.68–0.80]). Excellent stratification of patients with HNC into high, intermediate, and low mortality risk was achieved; with 5-year overall survival rates of 17–46% for the high-risk group compared to 92–98% for the low-risk group. The addition of morphological image feature further improved the performance (c-index = 0.73 [0.64–0.81]). These models are integrated in a clinic-ready interactive web interface: <ext-link xlink:href="https://uic-evl.github.io/hnc-predictor/" ext-link-type="uri">https://uic-evl.github.io/hnc-predictor/</ext-link></p>
      </sec>
      <sec id="S4">
        <title>Conclusions:</title>
        <p id="P6">Robust model-based prediction was able to stratify patients with HNC in distinct high, intermediate, and low mortality risk groups. This can effectively be capitalised for personalised radiotherapy, e.g., for tumour radiation dose escalation/de-escalation.</p>
      </sec>
    </abstract>
    <kwd-group>
      <kwd>Head and neck cancer</kwd>
      <kwd>Overall survival</kwd>
      <kwd>Machine learning</kwd>
      <kwd>Image biomarkers</kwd>
      <kwd>Decision support tool</kwd>
    </kwd-group>
  </article-meta>
</front>
<body>
  <sec id="S5">
    <label>1.</label>
    <title>Introduction</title>
    <p id="P7">Head and neck cancer (HNC) affects almost 650,000 individuals and causes 350,000 deaths worldwide annually [<xref rid="R1" ref-type="bibr">1</xref>]. Historically, the main etiological HNC risk factor was smoking; hence, HNC incidence rates were expected to decrease along with the decline in societal smoking [<xref rid="R2" ref-type="bibr">2</xref>–<xref rid="R5" ref-type="bibr">5</xref>]. Yet, HNC cases increased due to a relatively new epidemiological subtype, human papilloma virus (HPV)-related HNC, which affects relatively younger patients and is associated with much better prognosis compared to HPV-negative HNC [<xref rid="R6" ref-type="bibr">6</xref>,<xref rid="R7" ref-type="bibr">7</xref>].</p>
    <p id="P8">Radiotherapy is a cornerstone for curative HNC treatment. To date, a ‘one-dose-fits-all’ approach is deployed, i.e., all patients receive roughly similar tumour radiation dose prescription based mainly on historic pre-HPV clinical trials. Currently, personalising radiation dose to optimise tumour control is relatively unexplored. For instance, only tumour stage (i.e., early stage versus locally advanced) is used to select eligible patients in recent dose-escalation clinical trials, aiming to improve treatment control by increasing the radiation tumour dose [<xref rid="R8" ref-type="bibr">8</xref>–<xref rid="R11" ref-type="bibr">11</xref>]. The risk of severe radiation-induced sequelae from dose-escalation [<xref rid="R10" ref-type="bibr">10</xref>] makes improved selection a vital unmet need. On the other hand, patients with a low risk of treatment failure might benefit from de-intensified treatment, e.g., MR-guided dose de-escalation [<xref rid="R12" ref-type="bibr">12</xref>]. To date, attempts at therapeutic de-intensification in large heterogenous cohorts without patient-specific criteria have been uncompelling [<xref rid="R13" ref-type="bibr">13</xref>–<xref rid="R15" ref-type="bibr">15</xref>]; consequently, granular treatment outcome estimation for directed dose modification remains a substantive opportunity for HNC treatment personalisation.</p>
    <p id="P9">Robust treatment outcome prediction based on multifactorial clinical variables is thus crucial to improve treatment success and establish effective personalised radiotherapy [<xref rid="R16" ref-type="bibr">16</xref>,<xref rid="R17" ref-type="bibr">17</xref>]. While clinical models have been developed [<xref rid="R18" ref-type="bibr">18</xref>–<xref rid="R21" ref-type="bibr">21</xref>], they are largely unused; clinical implementation has been hampered due to the lack of clinically useful prediction tools that are backed by large representative multi-institutional dataset for training and validation. Additionally, radiomics features – tumour-specific characteristics quantified from medical images – have been shown to improve HNC treatment outcome prediction [<xref rid="R22" ref-type="bibr">22</xref>–<xref rid="R24" ref-type="bibr">24</xref>]. An approach to add imaging features to well-established clinical models is needed for robust radiomics applications.</p>
    <p id="P10">The main aim was to establish a large-scale multi-institutional standard for a more individualised outcome prediction in patients with HNC of overall survival (OS) and oncologic outcomes (i.e., local [LC] and regional control [RC]) following radiotherapy using large high-quality international datasets (&gt;4500 patients with HNC). Additionally, an interactive web-based risk prediction tool was pursued to make the models direct clinically actionable for clinicians. Finally, we present a <italic toggle="yes">serial</italic> prediction model approach, where the clinical models can be enriched by <italic toggle="yes">an optional imaging component</italic> (<xref rid="F1" ref-type="fig">Fig. 1A</xref>).</p>
  </sec>
  <sec id="S6">
    <label>2.</label>
    <title>Methods</title>
    <sec id="S7">
      <label>2.1.</label>
      <title>Patient considerations</title>
      <p id="P11">The MD Anderson Cancer Center (MDACC) Big Data Radiotherapy HNC collection effort has been initiated for this study. The prospective and retrospective data collection was approved by the MDACC Institutional Review Board [PA14-0947/RCR03-0800]. This dataset was used for training and independent validation. Prospectively collected data from the University Medical Center Groningen (UMCG) were used for external validation (Standardized Follow-up Program: <ext-link xlink:href="https://clinicaltrials.gov/ct2/show/NCT02435576" ext-link-type="uri">NCT02435576</ext-link>). The publicly available data from Princes Margret Hospital (PMH) on The Cancer Imaging Archive (TCIA) were used for additional external validation [<xref rid="R25" ref-type="bibr">25</xref>].</p>
      <p id="P12">Inclusion criteria for all cohorts included: (1) proven squamous cell carcinoma of the head and neck, (2) treatment with definitive or adjuvant radiotherapy with/without chemotherapy, and (3) no prior head and neck radiation. Patients were treated from 2001 to 2019, 2007 to 2020, and 2005 to 2010 at MDACC, UMCG, and PMH, respectively. Prescribed tumour doses were 60–72 Gy, as detailed previously by each institution [<xref rid="R23" ref-type="bibr">23</xref>,<xref rid="R26" ref-type="bibr">26</xref>,<xref rid="R27" ref-type="bibr">27</xref>].</p>
    </sec>
    <sec id="S8">
      <label>2.2.</label>
      <title>Outcome measures</title>
      <p id="P13">The primary prediction end-point was OS. The secondary end-points were LC and RC, which were defined as recurrent, progressive, or residual disease of the primary tumour or regional lymph nodes after radiotherapy, respectively (with death as a censor). Time-to-event was measured from start of radiotherapy until the event, alternatively data were censored at last follow-up date. Systematic follow-up was part of the standard of care in both treatment centres: every 3 months in year 1, followed by every 6 months thereafter.</p>
    </sec>
    <sec id="S9">
      <label>2.3.</label>
      <title>Clinical variables definitions</title>
      <p id="P14">The clinical variables (and categorisations) considered in this study were demarcated as follows: gender (female, male); age (&lt;55, 55–65, 65–75, &gt;75); performance score (0, 1, ≥2); smoking status (current, former, never); pack-years (&lt;5, 5–25, 26–50, &gt;50); T-stage (T0-1, T2, T3, T4); N-stage (N0-2a/b, N2c, N3); tumour site (oropharynx [OPC], larynx, hypopharynx, nasopharynx, oral cavity); HPV status (positive and negative), and tumour stage <italic toggle="yes">AJCC</italic><sup><italic toggle="yes">8th</italic></sup> (I, II, III, IV) [<xref rid="R28" ref-type="bibr">28</xref>]. The <italic toggle="yes">AJCC</italic><sup><italic toggle="yes">8th</italic></sup> staging was generated from the T-stage, N-stage, tumour site and HPV status with in-house developed algorithm (<xref rid="SD1" ref-type="supplementary-material">eMethods</xref>). If HPV status was unknown/unspecified, it was assumed as HPV-negative for non-OPC cases. Categorisation was determined on the Kaplan–Meier curves in the training data to meet adequate proportionality testing (<xref rid="SD1" ref-type="supplementary-material">eFig. 1</xref>).</p>
    </sec>
    <sec id="S10">
      <label>2.4.</label>
      <title>Statistical analysis</title>
      <p id="P15">The MDACC dataset was split into a training and independent validation cohort for the clinical model development (<xref rid="F1" ref-type="fig">Fig. 1B</xref>). The data with all variables collected (i.e., complete cases) were split with a 60:40 ratio into training:validation data. Cases with missing variables (i.e., partial cases) were added to the training set. Only complete cases were considered for the independent and external validation cohorts.</p>
      <p id="P16">Step-wise forward variable selection was employed to select variables for the Cox regression OS, LC, and RC model based on likelihood ratio test with a Bonferroni-corrected significance level of p &lt; 0.005. Repeated selection was performed on 10 imputed datasets using Multivariate Imputation by Chained Equations (R-package ‘mice’ v3.13.0) with predictive mean matching across 25 iterations [<xref rid="R29" ref-type="bibr">29</xref>]. Based on the variable selection and intervariable correlation results, potential models were tested in the validation cohorts. The final models were used for patient stratification. The final OS model was compared with a model based on <italic toggle="yes">AJCC</italic><sup><italic toggle="yes">8th</italic></sup> alone with the likelihood ratio test.</p>
    </sec>
    <sec id="S11">
      <label>2.5.</label>
      <title>Risk-based patient stratification</title>
      <p id="P17">Patients were stratified into high-, intermediate-, and low-risk groups based on the predicted 2-year mortality risk derived from the Cox regression clinical models. These 2-year mortality risk thresholds were visually determined in the training cohort by evaluating the Kaplan–Meier curves for the different risk groups.</p>
    </sec>
    <sec id="S12">
      <label>2.6.</label>
      <title>Imaging prediction component</title>
      <p id="P18">For a subset of patients with available pre-treatment contrast-enhanced CT scans, image characteristics of the primary tumour were quantified in geometric and texture radiomics features using previously developed libraries [<xref rid="R30" ref-type="bibr">30</xref>,<xref rid="R31" ref-type="bibr">31</xref>], according to the Image Biomarker Standardisation Initiative [<xref rid="R32" ref-type="bibr">32</xref>]. Features were selected with bootstrapped forward stepwise variable selection (1000 samples). Subsequently, model improvement was tested for the addition of these features to the clinical risk prediction (i.e., linear predictor).</p>
    </sec>
  </sec>
  <sec id="S13">
    <label>3.</label>
    <title>Results</title>
    <sec id="S14">
      <label>3.1.</label>
      <title>Patients</title>
      <p id="P19">A total of 4611 HNC patients were used for the analyses: training (MDACC; n = 2241), independent test (MDACC; n = 786), external validation cohort 1 (UMCG; n = 1087), and external validation cohort 2 (PMH; n = 497). Patient characteristics per cohort are shown in <xref rid="T1" ref-type="table">Table 1</xref>. Noteworthy differences between cohorts were seen in HPV status (ranging from 16 to 71%), OPC incidence (30–100%), and pack-years (μ = 20–31). Imputation of clinical variables was only performed in the training cohort for <italic toggle="yes">pack-years</italic> (5% missing), <italic toggle="yes">performance score</italic> (16%), and <italic toggle="yes">HPV status</italic> (19%). The overall median follow-up time was 3.6 year (interquartile range [IQR]: [1.6–6.0]), and for censored patients (i.e. excluding patients that die) only 4.3 year [IQR: 2.1–6.7] (site specific, MDACC: 4.1 [2.1–6.6], UMCG: 3.2 [1.7–5.1], and PMH: 8.0 [6.1–9.3]).</p>
    </sec>
    <sec id="S15">
      <label>3.2.</label>
      <title>Association of clinical variables and treatment outcome</title>
      <p id="P20">For OS, univariable analyses showed that all clinical variables were significant (p &lt; 0.0001), except <italic toggle="yes">gender</italic> (<xref rid="SD1" ref-type="supplementary-material">eTable 1</xref>). For LC or RC, all variables were significant, except <italic toggle="yes">age</italic> and <italic toggle="yes">gender</italic> (p &gt; 0.106), and <italic toggle="yes">N-stage</italic> for LC (p = 0.189).</p>
      <p id="P21">For comprehensive multivariable model analyses and iterations, please refer to <xref rid="SD1" ref-type="supplementary-material">eResults 1</xref>.</p>
      <p id="P22">For OS, the final model included the following clinicodemographic variables: <italic toggle="yes">performance score</italic>, <italic toggle="yes">AJCC</italic><sup><italic toggle="yes">8th</italic></sup>
<italic toggle="yes">stage</italic>, <italic toggle="yes">pack-years</italic>, and <italic toggle="yes">age</italic> (<xref rid="T2" ref-type="table">Table 2</xref>); note that <italic toggle="yes">AJCC</italic><sup><italic toggle="yes">8th</italic></sup>
<italic toggle="yes">stage</italic> is based on <italic toggle="yes">T</italic>- and <italic toggle="yes">N-stage</italic>, <italic toggle="yes">tumour site</italic>, and <italic toggle="yes">HPV-status</italic>. The performance of the OS clinical model was good in both the MDACC training (c-index = 0.72 95% CI [0.66–0.77]) and independent validation cohort (c-index = 0.76 [0.69–0.83]). External validation showed good performance in both the UMCG cohort (c-index = 0.73 [0.68–0.77]) and PMH cohort (c-index = 0.75 [0.68–0.80]). <italic toggle="yes">AJCC</italic><sup><italic toggle="yes">8th</italic></sup> staging alone was significantly inferior (p &lt; 0.0001) to clinical OS model with c-indices: training 0.65 [0.59–0.71]; test 0.72[0.64–0.80]; UMCG 0.67 [0.62–0.72]; PMH 0.69 [0.62–0.76].</p>
      <p id="P23">The final LC model contained <italic toggle="yes">T-stage</italic>, <italic toggle="yes">HPV status</italic>, <italic toggle="yes">performance score</italic>, and <italic toggle="yes">pack-years</italic>, with resultant c-indices: training: 0.74 [0.70–0.78]; testing: 0.71 [0.58–0.84]; external validation: 0.70 [0.62–0.76] (UMCG); and 0.74 [0.59–0.89) (PMH). T-stage (HR: T2, 4.19 [2.19–8.03]); T3, 4.36 [2.22–8.58]; T4, 5.02 [2.56–9.83]) and HPV status (HR: 0.5 [0.34–0.73]) were the most dominant factors in predicting LC.</p>
      <p id="P24">The final RC model included <italic toggle="yes">AJCC</italic><sup><italic toggle="yes">8th</italic></sup>
<italic toggle="yes">stage</italic>, <italic toggle="yes">tumour site</italic>, and <italic toggle="yes">performance score</italic> as component variables (<xref rid="T2" ref-type="table">Table 2</xref>). Resultant c-indices showed training: 0.74 [0.69–0.78]; testing: 0.73 [0.57–0.89]; external validation: 0.7 [0.62–0.77] (UMCG) and 0.71 [0.48–0.94] (PMH). While N-stage can be expected to be an important predictor for RC, the combination of tumour characteristics in the <italic toggle="yes">AJCC</italic><sup><italic toggle="yes">8th</italic></sup> outperformed N-stage alone.</p>
      <p id="P25">Overall, the calibration plots and HosmereLemeshow analyses showed good calibration of the models in the comparator cohort (<xref rid="SD1" ref-type="supplementary-material">eFig. 2</xref>). Yet, significant calibration deviation was seen for the OS model in the external cohorts.</p>
    </sec>
    <sec id="S16">
      <label>3.3.</label>
      <title>Model-based patient stratification</title>
      <p id="P26">The survival curves of patients stratified based on their model-based predicted 2-year mortality risk (2y-risk) are shown in <xref rid="F2" ref-type="fig">Fig. 2</xref>. Based on the training cohort, the best separation was seen for predicted 2y-risk lower than 5% (low-risk), between 5 and 25% (intermediate-risk), and higher than 25% (high risk). The average observed 5-year OS was 95% (range: 93–98%) for the low-risk group, 65% (58–79%) for the intermediate-risk group, and 29% (17–42%) for the high-risk group. Notably, the proportion of MDACC and PMH patients stratified as low risk (20% and 26%) was substantially larger compared to the UMCG patients (8%). See <xref rid="SD1" ref-type="supplementary-material">eFigures R1.2</xref> and <xref rid="SD1" ref-type="supplementary-material">R1.3</xref> for LC and RC analyses.</p>
      <p id="P27">Prediction based on AJCC<sup>8th</sup> staging alone gives a single 2y-risk per category (x-axis <xref rid="F3" ref-type="fig">Fig. 3</xref>-left), while a sizeable spread can be seen per category in 2y-risk calculated by the clinical model (y-axis). <xref rid="F3" ref-type="fig">Fig. 3</xref> shows that only a select portion of the Stage I is low risk (2y-risk&lt;5%), and limited number of Stage III-IV patients are high risk (2y-risk&gt;25%). The ‘by-the-model-identified’ high-risk patients were correctly classified as the majority of these patients died (<xref rid="F3" ref-type="fig">Fig. 3</xref>-right).</p>
    </sec>
    <sec id="S17">
      <label>3.4.</label>
      <title>Web interface prediction and stratification tool</title>
      <p id="P28">The clinically usable prediction tool was implemented in an interactive web interface <ext-link xlink:href="https://uic-evl.github.io/hnc-predictor/employing" ext-link-type="uri">https://uic-evl.github.io/hnc-predictor/employing</ext-link> the final clinical models. Here, the clinical variables of a new patient (e.g., age) can be interactively submitted, whereafter the patient-specific predicted OS, LC, or RC curves can be calculated. Finally, by submitting the desired 2-y risk threshold, the new patient is stratified into being low, intermediate, high risk of OS, LC, and/or RC.</p>
    </sec>
    <sec id="S18">
      <label>3.5.</label>
      <title>Models in tumour site sub cohorts</title>
      <p id="P29">The clinical models performed well in two largest sub-cohorts: OPC (n = 2930 patients) and larynx (n = 1257) with c-indices of 0.77/0.76/0.71 and 0.70/0.63/0.73 for OS/LC/RC, respectively (<xref rid="SD1" ref-type="supplementary-material">eFig. 3</xref>). The model performance (c-index: 0.66/0.67/0.64) was lower for the oral cavity patients (n = 805). Overall, the calibration of the models was good, yet the actual mortality risk was higher than predicted for the OPC and oral cavity patients (HosmereLemeshow p-value&lt;0.05), which was comparable to the total cohort. The number of hypopharynx (n = 136), nasopharynx (n = 56), and unknown primary (n = 73) patients was too low to draw reliable conclusions (<xref rid="SD1" ref-type="supplementary-material">eFig. 3</xref>).</p>
    </sec>
    <sec id="S19">
      <label>3.6.</label>
      <title>Imaging component</title>
      <p id="P30">For the radiomics features, 455 MDACC patients were used for training, and 229 UMCG and 430 PMH patients for external validation. The bootstrapped stepwise forward selection identified the ‘minor axis length’ of the primary tumour as the most frequently selected geometric predictor for OS (<xref rid="SD1" ref-type="supplementary-material">eResults 2</xref>). This image feature significantly added (likelihood ratio test; p = 0.004) to predicted risk from clinical model (i.e., linear predictor). Compared to the clinical model (c-index = 0.72 [0.63–0.81]), the performance of this combined model increased slightly (c-index 0.73 [0.64–0.81]). While the validation c-index increase was more pronounced in the UMCG cohort (from 0.71 [0.62–0.81] to 0.74 [0.64–0.83]), no performance improvement was seen in the PMH validation cohort (from 0.74 [0.67–0.80] to 0.74 [0.67–0.81]). No robust features could be identified for LC and RC (<xref rid="SD1" ref-type="supplementary-material">eResults 2</xref>).</p>
    </sec>
  </sec>
  <sec id="S20">
    <label>4.</label>
    <title>Discussion</title>
    <p id="P31">The clear stratification of patients with HNC into high, intermediate, and low risk of mortality (<xref rid="F2" ref-type="fig">Fig. 2</xref>) by the models can be effectively used for personalised radiotherapy, e.g., selecting high-risk patients for tumour radiation dose escalation or low-risk patients for dose de-escalation. The impressive survival differences for patients who are nominally in the same AJCC (including HPV) risk category allows for more directive and granular patient-by-patient risk differentiation. For example, OPC HPV-positive patients are considered for de-escalation trials [<xref rid="R13" ref-type="bibr">13</xref>–<xref rid="R15" ref-type="bibr">15</xref>], yet our findings show that 4% and 14% of these patients have a 2-y mortality of &gt;25% and &gt;15%, respectively, for which dose de-escalation may not be advisable. By using this international big dataset of more than 4500 patients, this study establishes a benchmark for robust OS, LC, and RC prediction in patients with HNC. Additionally, the clinic-ready web-based tool calculates and visualises the expected survival and tumour outcome for new individual patients (<ext-link xlink:href="https://uic-evl.github.io/hnc-predictor/" ext-link-type="uri">https://uic-evl.github.io/hnc-predictor/</ext-link>). The underlying model code, radiomics, and clinical data are publicly shared in a Figshare repository: <ext-link xlink:href="10.6084/m9.figshare.21303000" ext-link-type="doi">https://doi.org/10.6084/m9.figshare.21303000</ext-link>.</p>
    <p id="P32">All final clinical models included the patient’s <italic toggle="yes">performance score</italic>; that poor(er) performance scores are associated with poorer survival has been long recognised [<xref rid="R33" ref-type="bibr">33</xref>,<xref rid="R34" ref-type="bibr">34</xref>], yet that tumour control is associated with performance status is less intuitive. The composite variable <italic toggle="yes">AJCC</italic><sup><italic toggle="yes">8th</italic></sup>
<italic toggle="yes">staging</italic> together with <italic toggle="yes">pack-years</italic>, <italic toggle="yes">age</italic>, and <italic toggle="yes">performance score</italic> were included in the OS model; hence, all clinical variables were directly or indirectly incorporated in this model, except gender. Similar OS risk factors have been observed in previous studies, age, tumour location, smoking status, T and N-stage [<xref rid="R20" ref-type="bibr">20</xref>,<xref rid="R35" ref-type="bibr">35</xref>], and later HPV status [<xref rid="R18" ref-type="bibr">18</xref>,<xref rid="R19" ref-type="bibr">19</xref>]. Beesley <italic toggle="yes">et al.</italic> developed a US-trained/EU-validated multistate Bayesian clinical prediction model for radiotherapy OPC patients to predict event likelihood parameters [<xref rid="R36" ref-type="bibr">36</xref>]. While the modelling procedure was quite different, similar input predictors were identified: T, N-stage, HPV status, age, smoking status; notably, tobacco pack-years and performance score were not included. Overall, these findings suggest that despite distinct modelling approaches and datasets, convergent phenomena have been observed.</p>
    <p id="P33">For the LC prediction, <italic toggle="yes">T-stage</italic>, <italic toggle="yes">HPV status</italic>, <italic toggle="yes">performance score</italic>, and <italic toggle="yes">pack-years</italic> were selected. Since <italic toggle="yes">HPV status</italic> was highly correlated to <italic toggle="yes">tumour site</italic> (Rho = 0.89; p &lt; 0.0001), it is difficult to determine the impact of tumour location on LC. In contrast, for RC, tumour site showed added predictive value to <italic toggle="yes">AJCC</italic><sup><italic toggle="yes">8th</italic></sup> staging, which is interesting as it based on the tumour site. This is likely due to the difference of the lymphatic tumour spread per tumour location [<xref rid="R37" ref-type="bibr">37</xref>].</p>
    <p id="P34">Outcome prediction was robust across multi-institutional cohorts, even though they had distinct patient demographic profiles (<xref rid="T1" ref-type="table">Table 1</xref>); particularly, the HPV-positive HNC incidence was substantially lower in European compared to the North American cohorts. Additionally, OPC, larynx, and oral cavity cancer sub-analyses (<xref rid="SD1" ref-type="supplementary-material">eFig. 3</xref>) showed clinical applicable levels of model performance and calibration. For the hypopharynx, nasopharynx, and unknown primary cancer sub-cohorts, caution is advised when applying these models due to the sparse patient numbers.</p>
    <p id="P35">The serial approach of building the prediction model presented in this study (<xref rid="F1" ref-type="fig">Fig. 1A</xref>) allows for flexible addition of imaging features. Higher OS risk was associated with larger <italic toggle="yes">minor axis length</italic> of the tumour [<xref rid="R32" ref-type="bibr">32</xref>], which represents an intuitive metric for tumour size. Previous studies showed the relation between OS and features indicating larger or more irregular tumours [<xref rid="R22" ref-type="bibr">22</xref>,<xref rid="R23" ref-type="bibr">23</xref>]. Texture features, in contrast to prior works [<xref rid="R22" ref-type="bibr">22</xref>–<xref rid="R24" ref-type="bibr">24</xref>], failed to improve our model discrimination (<xref rid="SD1" ref-type="supplementary-material">eResults 2.2</xref>); similar to a previous study [<xref rid="R38" ref-type="bibr">38</xref>]. This may be due to the sensitivity of intensity/texture features to image acquisition discrepancies [<xref rid="R39" ref-type="bibr">39</xref>], arguing for improved image harmonisation, standardisation, and image quality.</p>
    <p id="P36">Limitations of the study cohort are that the majority of tumour locations were OPC, larynx, and oral cavity, underrepresenting hypopharynx, nasopharynx, and unknown primary cases. While this is a representative of the HNC clinical incidence, this may mean that the presented models are not sufficiently tested for under-represented tumour sites. Another challenge is the definition of local and RC, for which an event was broadly defined as recurrent, progressive, or residual disease. The detection residual/returning disease can be challenging [<xref rid="R40" ref-type="bibr">40</xref>] and is further complicated when no salvage treatments are available or when patients are lost from follow-up, and thus, no pathologic conformation, clinical progression, or imaging can be obtained. This may therefore potentially result in an underdetection bias of disease control in the cohorts, which can influence accuracy of the LC and RC models.</p>
    <p id="P37">As with multi-site data aggregation and risk modelling efforts at large scale, there are intrinsic limitations as function of data availability, e.g., anaemia identified by Beesley <italic toggle="yes">et al.</italic> was not recorded in these datasets [<xref rid="R36" ref-type="bibr">36</xref>]. Consequently, the utility of this (or any) predictive model is necessarily predicated on input variables and could be modified or altered with updated or augmented data. Moreover, stage migration considerations between AJCC 7th and 8th edition should be noted; for example, extranodal extension was not always specified/recorded as a formalised component of AJCC 7th ed. and may have been obscured. Improved incorporation could improve the models, or alternatively, it could be added as a separate variable [<xref rid="R36" ref-type="bibr">36</xref>]. While we focus on OS, LC, and RC, future work will focus on predicting distant metastases and disease-free survival.</p>
    <p id="P38">Nonetheless, this study is to our knowledge based on the largest head and neck extant multi-site dataset, which allowed for the development of statistically robust and clinic-ready HNC risk models. This provides a benchmark platform for extended future developments of image-incorporating prediction methods, such as deep learning. Moreover, the end-user-enabled web interface (GUI) provides an accessible decision support tool for patient-individual risk stratification for therapeutic selection.</p>
  </sec>
  <sec id="S21">
    <label>5.</label>
    <title>Conclusion</title>
    <p id="P39">Developed and assessed in this international ‘big-data’-set, our prediction models presented excellent capacity to stratify patients with HNC at high, intermediate, and low mortality risk – outperforming <italic toggle="yes">AJCC</italic><sup><italic toggle="yes">8th</italic></sup> staging. This work sets a benchmark for robust OS, LC, and RC risk prediction in radiotherapy HNC patients, which can effectively be capitalised for personalised radiotherapy with the clinic-ready web-based tool prediction tool for new patients that does not require under-the-hood knowledge of model mechanics (<ext-link xlink:href="https://uic-evl.github.io/hnc-predictor/" ext-link-type="uri">https://uic-evl.github.io/hnc-predictor/</ext-link>).</p>
  </sec>
  <sec sec-type="supplementary-material" id="SM1">
    <title>Supplementary Material</title>
    <supplementary-material id="SD1" position="float" content-type="local-data">
      <label>Appendix A. Supplementary data</label>
      <media xlink:href="NIHMS1864360-supplement-Appendix_A__Supplementary_data.docx" id="d64e801" position="anchor"/>
    </supplementary-material>
  </sec>
</body>
<back>
  <ack id="S22">
    <title>Acknowledgements</title>
    <p id="P40">The authors thank the MD Anderson Stiefel Center for Oropharyngeal Cancer Research and Education (MDA-SCORE) for the additional prospectively collected data. The authors also thank the MDACC summer students of 2019 for the aid in collecting part of the clinical variable data.</p>
    <sec id="S23">
      <title>Funding statement</title>
      <p id="P41">Dr. van Dijk received funding and salary support from the Dutch organization NWO ZonMw for the execution of this study via the Rubicon Individual career development grant.</p>
      <p id="P42">Dr. Mohamed and Dr. Fuller received funding and salary support from directly related to this project from: NIH National Institute of Dental and Craniofacial Research (NIDCR) Academic Industrial Partnership Grant (R01DE028290); NIDCR Establishing Outcome Measures for Clinical Studies of Oral and Craniofacial Diseases and Conditions award (R01DE025248); NIH/NSF NCI Smart Connected Health Program (R01CA257814).</p>
      <p id="P43">Dr. Fuller received funding and salary support from directly unrelated to this project from: NCI Parent Research Project Grant (R01CA258827); NCI Ruth L. Kirschstein RSNA, United states Institutional Research Training Grant (T32CA261856); NIH NIDCR Exploratory/Developmental Research Grant Program (R21DE031082); National Institutes of Health (NIH) National Cancer Institute (NCI) Early Stage Development of Technologies in Biomedical Computing, Informatics, and Big Data Science Program (R01CA214825); NSF/NIH Joint Initiative on Quantitative Approaches to Biomedical Big Data program (R01CA225190); NIH National Institute of Biomedical Imaging and Bioengineering (NIBIB) Research Education Programs for Residents and Clinical Fellows Grant (R25EB025787); NCI Early Phase Clinical Trials in Imaging and Image-Guided Interventions Program (1R01CA218148); NIH/NCI Cancer Center Support Grant (CCSG) Pilot Research Program Award from the UT MD Anderson CCSG Radiation Oncology and Cancer Imaging Program (P30CA016672); Small Business Innovation Research Grant Program a sub-award from Oncospace, Inc. (R43CA254559); The Human BioMolecular Atlas Program (HuBMAP) Integration, Visualization and Engagement (HIVE) Initiative (OT2OD026675) sub-award; Patient-Centered Outcomes Research Institute (PCS-1609-36,195) sub-award from Princess Margaret Hospital; National Science Foundation (NSF) Division of Civil, Mechanical, and Manufacturing Innovation (CMMI) grant (NSF 1933369). Dr. Fuller receives grant and infrastructure support from MD Anderson Cancer Center via: the Charles and Daneen Stiefel Center for Head and Neck Cancer Oropharyngeal Cancer Research Program; the Program in Image-guided Cancer Therapy; and the NIH/NCI Cancer Center Support Grant (CCSG) Radiation Oncology and Cancer Imaging Program (P30CA016672).</p>
      <p id="P44">Mr. Nipu and Dr. Marai received funding unrelated to this project during the period of the study execution from: the U.S. National Institutes of Health (NIH) National Cancer Institute (NCI) (R01CA258827, R01CA225190), from the NIH National Library of Medicine (NLM) (R01LM012527), and from the U.S. National Science Foundation (CDS&amp;E-1854815, CNS-1828265).</p>
      <p id="P45">Mr. Wahid is supported by the Dr. John J. Kopchick Fellowship through The University of Texas MD Anderson UTHealth Graduate School of Biomedical Sciences, the American Legion Auxiliary Fellowship in Cancer Research, and an NIH/National Institute for Dental and Craniofacial Research (NIDCR) F31 fellowship (1 F31DE031502-01).</p>
      <p id="P46">Prof. Langendijk received unrelated funding from the Dutch Cancer Society and the European Union during this study.</p>
    </sec>
  </ack>
  <fn-group>
    <fn fn-type="COI-statement" id="FN2">
      <p id="P47">Conflict of interest statement</p>
      <p id="P48">Dr. Fuller has received direct industry grant/in-kind support, honoraria and travel funding from Elekta AB. Prof. Langendijk was member of the Global Advisory Board of IBA (honorarium paid to the UMCG Research BV and the RayCare International Advisory Board of RaySearch). The department of Radiation Oncology of UMCG has research agreements with IBA, RaySearch, Siemens, Elekta, Mirada, and Leoni. All other authors declare no conflict of interest.</p>
    </fn>
    <fn id="FN3">
      <p id="P49">Appendix A. Supplementary data</p>
      <p id="P50">Supplementary data to this article can be found online at <ext-link xlink:href="10.1016/j.ejca.2022.10.011" ext-link-type="doi">https://doi.org/10.1016/j.ejca.2022.10.011</ext-link>.</p>
    </fn>
  </fn-group>
  <ref-list>
    <title>References</title>
    <ref id="R1">
      <label>[1]</label>
      <mixed-citation publication-type="journal"><name><surname>Sung</surname><given-names>H</given-names></name>, <name><surname>Ferlay</surname><given-names>J</given-names></name>, <name><surname>Siegel</surname><given-names>RL</given-names></name>, <name><surname>Laversanne</surname><given-names>M</given-names></name>, <name><surname>Soerjomataram</surname><given-names>I</given-names></name>, <name><surname>Jemal</surname><given-names>A</given-names></name>, <etal/><article-title>Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.</article-title><source>CA Cancer J Clin</source><year>2021</year>;<volume>71</volume>:<fpage>209</fpage>–<lpage>49</lpage>.<pub-id pub-id-type="pmid">33538338</pub-id></mixed-citation>
    </ref>
    <ref id="R2">
      <label>[2]</label>
      <mixed-citation publication-type="journal"><name><surname>Wyss</surname><given-names>A</given-names></name>, <name><surname>Hashibe</surname><given-names>M</given-names></name>, <name><surname>Chuang</surname><given-names>S-C</given-names></name>, <name><surname>Lee</surname><given-names>Y-CA</given-names></name>, <name><surname>Zhang</surname><given-names>Z-F</given-names></name>, <name><surname>Yu</surname><given-names>G-P</given-names></name>, <etal/><article-title>Cigarette, cigar, and pipe smoking and the risk of head and neck cancers: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium.</article-title><source>Am J Epidemiol</source><year>2013</year>; <volume>178</volume>:<fpage>679</fpage>–<lpage>90</lpage>.<pub-id pub-id-type="pmid">23817919</pub-id></mixed-citation>
    </ref>
    <ref id="R3">
      <label>[3]</label>
      <mixed-citation publication-type="journal"><name><surname>Jamal</surname><given-names>A</given-names></name>, <name><surname>King</surname><given-names>BA</given-names></name>, <name><surname>Neff</surname><given-names>LJ</given-names></name>, <name><surname>Whitmill</surname><given-names>J</given-names></name>, <name><surname>Babb</surname><given-names>SD</given-names></name>, <name><surname>Graffunder</surname><given-names>CM</given-names></name>. <article-title>Current cigarette smoking among adults — United States, 2005–2015.</article-title><source>MMWR Morb Mortal Wkly Rep</source><year>2016</year>;<volume>65</volume>.</mixed-citation>
    </ref>
    <ref id="R4">
      <label>[4]</label>
      <mixed-citation publication-type="journal"><article-title>Current cigarette smoking among adults—United States, 2011.</article-title><source>JAMA</source><year>2013</year>;<volume>309</volume>:<fpage>539</fpage>.</mixed-citation>
    </ref>
    <ref id="R5">
      <label>[5]</label>
      <mixed-citation publication-type="journal"><name><surname>Marur</surname><given-names>S</given-names></name>, <name><surname>Forastiere</surname><given-names>AA</given-names></name>. <article-title>Head and neck cancer: changing epidemiology, diagnosis, and treatment.</article-title><source>Mayo Clin Proc</source><year>2008</year>;<volume>83</volume>: <fpage>489</fpage>–<lpage>501</lpage>.<pub-id pub-id-type="pmid">18380996</pub-id></mixed-citation>
    </ref>
    <ref id="R6">
      <label>[6]</label>
      <mixed-citation publication-type="journal"><name><surname>Benson</surname><given-names>E</given-names></name>, <name><surname>Li</surname><given-names>R</given-names></name>, <name><surname>Eisele</surname><given-names>D</given-names></name>, <name><surname>Fakhry</surname><given-names>C</given-names></name>. <article-title>The clinical impact of HPV tumor status upon head and neck squamous cell carcinomas.</article-title><source>Oral Oncol</source><year>2014</year>;<volume>50</volume>:<fpage>565</fpage>–<lpage>74</lpage>.<pub-id pub-id-type="pmid">24134947</pub-id></mixed-citation>
    </ref>
    <ref id="R7">
      <label>[7]</label>
      <mixed-citation publication-type="journal"><name><surname>Marur</surname><given-names>S</given-names></name>, <name><surname>D’Souza</surname><given-names>G</given-names></name>, <name><surname>Westra</surname><given-names>WH</given-names></name>, <name><surname>Forastiere</surname><given-names>AA</given-names></name>. <article-title>HPV-associated head and neck cancer: a virus-related cancer epidemic.</article-title><source>Lancet Oncol</source><year>2010</year>;<volume>11</volume>:<fpage>781</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">20451455</pub-id></mixed-citation>
    </ref>
    <ref id="R8">
      <label>[8]</label>
      <mixed-citation publication-type="journal"><name><surname>Bourhis</surname><given-names>J</given-names></name>, <name><surname>Overgaard</surname><given-names>J</given-names></name>, <name><surname>Audry</surname><given-names>H</given-names></name>, <name><surname>Ang</surname><given-names>KK</given-names></name>, <name><surname>Saunders</surname><given-names>M</given-names></name>, <name><surname>Bernier</surname><given-names>J</given-names></name>, <etal/><article-title>Hyperfractionated or accelerated radiotherapy in head and neck cancer : a meta-analysis.</article-title><source>Lancet</source><year>2006</year>;<volume>368</volume>:<fpage>843</fpage>–<lpage>54</lpage>.<pub-id pub-id-type="pmid">16950362</pub-id></mixed-citation>
    </ref>
    <ref id="R9">
      <label>[9]</label>
      <mixed-citation publication-type="journal"><name><surname>Horiot</surname><given-names>JC</given-names></name>, <name><surname>Le Fur</surname><given-names>R</given-names></name>, <name><surname>N’Guyen</surname><given-names>T</given-names></name>, <name><surname>Chenal</surname><given-names>C</given-names></name>, <name><surname>Schraub</surname><given-names>S</given-names></name>, <name><surname>Alfonsi</surname><given-names>S</given-names></name>, <etal/><article-title>Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapy.</article-title><source>Radiother Oncol</source><year>1992</year>;<volume>25</volume>:<fpage>231</fpage>–<lpage>41</lpage>.<pub-id pub-id-type="pmid">1480768</pub-id></mixed-citation>
    </ref>
    <ref id="R10">
      <label>[10]</label>
      <mixed-citation publication-type="journal"><name><surname>Madani</surname><given-names>I</given-names></name>, <name><surname>Duprez</surname><given-names>F</given-names></name>, <name><surname>Boterberg</surname><given-names>T</given-names></name>, <name><surname>van de Wiele</surname><given-names>C</given-names></name>, <name><surname>Bonte</surname><given-names>K</given-names></name>, <name><surname>Deron</surname><given-names>P</given-names></name>, <etal/><article-title>Maximum tolerated dose in a phase I trial on adaptive dose painting by numbers for head and neck cancer q.</article-title><source>Radiother Oncol</source><year>2011</year>;<volume>101</volume>:<fpage>351</fpage>–<lpage>5</lpage>.<pub-id pub-id-type="pmid">21742392</pub-id></mixed-citation>
    </ref>
    <ref id="R11">
      <label>[11]</label>
      <mixed-citation publication-type="journal"><name><surname>Guerrero Urbano</surname><given-names>T</given-names></name>, <name><surname>Clark</surname><given-names>CH</given-names></name>, <name><surname>Hansen</surname><given-names>VN</given-names></name>, <name><surname>Adams</surname><given-names>EJ</given-names></name>, <name><surname>A’Hern</surname><given-names>R</given-names></name>, <name><surname>Miles</surname><given-names>EA</given-names></name>, <etal/><article-title>A phase I study of dose-escalated chemoradiation with accelerated intensity modulated radiotherapy in locally advanced head and neck cancer.</article-title><source>Radiother Oncol</source><year>2007</year>;<volume>85</volume>:<fpage>36</fpage>–<lpage>41</lpage>.<pub-id pub-id-type="pmid">17709149</pub-id></mixed-citation>
    </ref>
    <ref id="R12">
      <label>[12]</label>
      <mixed-citation publication-type="journal"><name><surname>Bahig</surname><given-names>H</given-names></name>, <name><surname>Yuan</surname><given-names>Y</given-names></name>, <name><surname>Mohamed</surname><given-names>ASR</given-names></name>, <name><surname>Brock</surname><given-names>KK</given-names></name>, <name><surname>Ping</surname><given-names>S</given-names></name>, <name><surname>Wang</surname><given-names>J</given-names></name>, <etal/><article-title>Clinical and translational radiation oncology magnetic resonance-based response assessment and dose adaptation in human papilloma virus positive tumors of the oropharynx treated with radiotherapy (MR-ADAPTOR): an R-IDEAL stage 2a-2b/bayesian phase II.</article-title><source>Clin Transl Radiat Oncol</source><year>2018</year>;<volume>13</volume>:<fpage>19</fpage>–<lpage>23</lpage>.<pub-id pub-id-type="pmid">30386824</pub-id></mixed-citation>
    </ref>
    <ref id="R13">
      <label>[13]</label>
      <mixed-citation publication-type="journal"><name><surname>Gillison</surname><given-names>ML</given-names></name>, <name><surname>Trotti</surname><given-names>AM</given-names></name>, <name><surname>Harris</surname><given-names>J</given-names></name>, <name><surname>Eisbruch</surname><given-names>A</given-names></name>, <name><surname>Harari</surname><given-names>PM</given-names></name>, <name><surname>Adelstein</surname><given-names>DJ</given-names></name>, <etal/><article-title>Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial.</article-title><source>Lancet</source><year>2019</year>;<volume>393</volume>:<fpage>40</fpage>–<lpage>50</lpage>.<pub-id pub-id-type="pmid">30449625</pub-id></mixed-citation>
    </ref>
    <ref id="R14">
      <label>[14]</label>
      <mixed-citation publication-type="journal"><name><surname>Mehanna</surname><given-names>H</given-names></name>, <name><surname>Robinson</surname><given-names>M</given-names></name>, <name><surname>Hartley</surname><given-names>A</given-names></name>, <name><surname>Kong</surname><given-names>A</given-names></name>, <name><surname>Foran</surname><given-names>B</given-names></name>, <name><surname>Fulton-Lieuw</surname><given-names>T</given-names></name>, <etal/><article-title>Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial.</article-title><source>Lancet</source><year>2019</year>;<volume>393</volume>:<fpage>51</fpage>–<lpage>60</lpage>.<pub-id pub-id-type="pmid">30449623</pub-id></mixed-citation>
    </ref>
    <ref id="R15">
      <label>[15]</label>
      <mixed-citation publication-type="journal"><name><surname>Yom</surname><given-names>SS</given-names></name>, <name><surname>Torres-Saavedra</surname><given-names>P</given-names></name>, <name><surname>Caudell</surname><given-names>JJ</given-names></name>, <name><surname>Waldron</surname><given-names>JN</given-names></name>, <name><surname>Gillison</surname><given-names>ML</given-names></name>, <name><surname>Xia</surname><given-names>P</given-names></name>, <etal/><article-title>Reduced-dose radiation therapy for HPV-associated oropharyngeal carcinoma (NRG oncology HN002).</article-title><source>J Clin Oncol</source><year>2021</year>;<volume>39</volume>:<fpage>956</fpage>–<lpage>65</lpage>.<pub-id pub-id-type="pmid">33507809</pub-id></mixed-citation>
    </ref>
    <ref id="R16">
      <label>[16]</label>
      <mixed-citation publication-type="journal"><name><surname>Heukelom</surname><given-names>J</given-names></name>, <name><surname>Hamming</surname><given-names>O</given-names></name>, <name><surname>Bartelink</surname><given-names>H</given-names></name>, <name><surname>Hoebers</surname><given-names>F</given-names></name>, <name><surname>Giralt</surname><given-names>J</given-names></name>, <name><surname>Herlestam</surname><given-names>T</given-names></name>, <etal/><article-title>Adaptive and innovative Radiation Treatment FOR improving Cancer treatment outcomE (ARTFORCE); a randomized controlled phase II trial for individualized treatment of head and neck cancer.</article-title><source>BMC Cancer</source><year>2013</year>;<volume>13</volume>:<fpage>1</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="pmid">23282137</pub-id></mixed-citation>
    </ref>
    <ref id="R17">
      <label>[17]</label>
      <mixed-citation publication-type="journal"><name><surname>Thorwarth</surname><given-names>D</given-names></name>, <name><surname>Soukup</surname><given-names>M</given-names></name>, <name><surname>Alber</surname><given-names>M</given-names></name>. <article-title>Dose painting with IMPT, helical tomotherapy and IMXT: a dosimetric comparison.</article-title><source>Radiother Oncol</source><year>2008</year>;<volume>86</volume>:<fpage>30</fpage>–<lpage>4</lpage>.<pub-id pub-id-type="pmid">18061294</pub-id></mixed-citation>
    </ref>
    <ref id="R18">
      <label>[18]</label>
      <mixed-citation publication-type="journal"><name><surname>Fakhry</surname><given-names>C</given-names></name>, <name><surname>Zhang</surname><given-names>Q</given-names></name>, <name><surname>Nguyen-Tân</surname><given-names>PF</given-names></name>, <name><surname>Rosenthal</surname><given-names>DI</given-names></name>, <name><surname>Weber</surname><given-names>RS</given-names></name>, <name><surname>Lambert</surname><given-names>L</given-names></name>, <etal/><article-title>Development and validation of nomograms predictive of overall and progression-free survival in patients with oropharyngeal cancer.</article-title><source>J Clin Oncol</source><year>2017</year>;<volume>35</volume>:<fpage>4057</fpage>–<lpage>65</lpage>.<pub-id pub-id-type="pmid">28777690</pub-id></mixed-citation>
    </ref>
    <ref id="R19">
      <label>[19]</label>
      <mixed-citation publication-type="journal"><name><surname>Prince</surname><given-names>V</given-names></name>, <name><surname>Bellile</surname><given-names>EL</given-names></name>, <name><surname>Sun</surname><given-names>Y</given-names></name>, <name><surname>Wolf</surname><given-names>GT</given-names></name>, <name><surname>Hoban</surname><given-names>CW</given-names></name>, <name><surname>Shuman</surname><given-names>AG</given-names></name>, <etal/><article-title>Individualized risk prediction of outcomes for oral cavity cancer patients.</article-title><source>Oral Oncol</source><year>2016</year>;<volume>63</volume>:<fpage>66</fpage>–<lpage>73</lpage>.<pub-id pub-id-type="pmid">27939002</pub-id></mixed-citation>
    </ref>
    <ref id="R20">
      <label>[20]</label>
      <mixed-citation publication-type="journal"><name><surname>Emerick</surname><given-names>KS</given-names></name>, <name><surname>Leavitt</surname><given-names>ER</given-names></name>, <name><surname>Michaelson</surname><given-names>JS</given-names></name>, <name><surname>Diephuis</surname><given-names>B</given-names></name>, <name><surname>Clark</surname><given-names>JR</given-names></name>, <name><surname>Deschler</surname><given-names>DG</given-names></name>. <article-title>Initial clinical findings of a mathematical model to predict survival of head and neck cancer.</article-title><source>Otolaryngol Head Neck Surg</source><year>2013</year>;<volume>149</volume>:<fpage>572</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="pmid">23797612</pub-id></mixed-citation>
    </ref>
    <ref id="R21">
      <label>[21]</label>
      <mixed-citation publication-type="journal"><name><surname>Jan</surname><given-names>R</given-names></name>, <name><surname>Jong</surname><given-names>B de</given-names></name>, <name><surname>Hermans</surname><given-names>J</given-names></name>, <name><surname>Molenaar</surname><given-names>J</given-names></name>, <name><surname>r</surname><given-names>JJ</given-names></name>, <name><surname>Cessie</surname><given-names>S</given-names></name>. <source>Prediction of survival in patients with head and neck cancer</source><year>2001</year>. p. <fpage>718</fpage>–<lpage>24</lpage>.</mixed-citation>
    </ref>
    <ref id="R22">
      <label>[22]</label>
      <mixed-citation publication-type="journal"><name><surname>Aerts</surname><given-names>HJWL</given-names></name>, <name><surname>Velazquez</surname><given-names>ER</given-names></name>, <name><surname>Leijenaar</surname><given-names>RTH</given-names></name>, <name><surname>Parmar</surname><given-names>C</given-names></name>, <name><surname>Grossmann</surname><given-names>P</given-names></name>, <name><surname>Cavalho</surname><given-names>S</given-names></name>, <etal/><article-title>Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach.</article-title><source>Nat Commun</source><year>2014</year>;<volume>5</volume>.</mixed-citation>
    </ref>
    <ref id="R23">
      <label>[23]</label>
      <mixed-citation publication-type="journal"><name><surname>Zhai</surname><given-names>T-T</given-names></name>, <name><surname>van Dijk</surname><given-names>LV</given-names></name>, <name><surname>Huang</surname><given-names>B-T</given-names></name>, <name><surname>Lin</surname><given-names>Z-X</given-names></name>, <name><surname>Ribeiro</surname><given-names>CO</given-names></name>, <name><surname>Brouwer</surname><given-names>CL</given-names></name>, <etal/><article-title>Improving the prediction of overall survival for head and neck cancer patients using image biomarkers in combination with clinical parameters.</article-title><source>Radiother Oncol</source><year>2017</year>; <volume>124</volume>:<fpage>256</fpage>–<lpage>62</lpage>.<pub-id pub-id-type="pmid">28764926</pub-id></mixed-citation>
    </ref>
    <ref id="R24">
      <label>[24]</label>
      <mixed-citation publication-type="journal"><name><surname>Valliéres</surname><given-names>M</given-names></name>, <name><surname>Kay-Rivest</surname><given-names>E</given-names></name>, <name><surname>Perrin</surname><given-names>LJ</given-names></name>, <name><surname>Liem</surname><given-names>X</given-names></name>, <name><surname>Furstoss</surname><given-names>C</given-names></name>, <name><surname>Aerts</surname><given-names>HJWL</given-names></name>, <etal/><article-title>Radiomics strategies for risk assessment of tumour failure in head-and-neck cancer.</article-title><source>Sci Rep</source><year>2017</year>;<volume>7</volume>:<fpage>1</fpage>–<lpage>14</lpage>.<pub-id pub-id-type="pmid">28127051</pub-id></mixed-citation>
    </ref>
    <ref id="R25">
      <label>[25]</label>
      <mixed-citation publication-type="journal"><name><surname>Kwan</surname><given-names>J</given-names></name>, <name><surname>Su</surname><given-names>J</given-names></name>, <name><surname>Huang</surname><given-names>S</given-names></name>, <name><surname>Ghoraie</surname><given-names>L</given-names></name>, <name><surname>Xu</surname><given-names>W</given-names></name>, <name><surname>Chan</surname><given-names>B</given-names></name>, <etal/><article-title>Data from radiomic biomarkers to refine risk models for distant metastasis in oropharyngeal carcinoma.</article-title><source>The Cancer Imaging Archive</source><year>2019</year>. DOI: <comment>10.79.</comment></mixed-citation>
    </ref>
    <ref id="R26">
      <label>[26]</label>
      <mixed-citation publication-type="journal"><name><surname>Mohamed</surname><given-names>ASR</given-names></name>, <name><surname>Cardenas</surname><given-names>CE</given-names></name>, <name><surname>Garden</surname><given-names>AS</given-names></name>, <name><surname>Awan</surname><given-names>MJ</given-names></name>, <name><surname>Rock</surname><given-names>CD</given-names></name>, <name><surname>Westergaard</surname><given-names>Sa</given-names></name>, <etal/><article-title>Patterns-of-failure guided biological target volume definition for head and neck cancer patients: FDG-PET and dosimetric analysis of dose escalation candidate subregions.</article-title><source>Radiother Oncol</source><year>2017</year>;<volume>124</volume>:<fpage>248</fpage>–<lpage>55</lpage>.<pub-id pub-id-type="pmid">28774596</pub-id></mixed-citation>
    </ref>
    <ref id="R27">
      <label>[27]</label>
      <mixed-citation publication-type="journal"><name><surname>O’Sullivan</surname><given-names>B</given-names></name>, <name><surname>Huang</surname><given-names>SH</given-names></name>, <name><surname>Perez-Ordonez</surname><given-names>B</given-names></name>, <name><surname>Massey</surname><given-names>C</given-names></name>, <name><surname>Siu</surname><given-names>LL</given-names></name>, <name><surname>Weinreb</surname><given-names>I</given-names></name>, <etal/><article-title>Outcomes of HPV-related oropharyngeal cancer patients treated by radiotherapy alone using altered fractionation.</article-title><source>Radiother Oncol</source><year>2012</year>;<volume>103</volume>:<fpage>49</fpage>–<lpage>56</lpage>.<pub-id pub-id-type="pmid">22410204</pub-id></mixed-citation>
    </ref>
    <ref id="R28">
      <label>[28]</label>
      <mixed-citation publication-type="journal"><name><surname>Amin</surname><given-names>MB</given-names></name>, <name><surname>Greene</surname><given-names>FL</given-names></name>, <name><surname>Edge</surname><given-names>SB</given-names></name>, <name><surname>Compton</surname><given-names>CC</given-names></name>, <name><surname>Gershenwald</surname><given-names>JE</given-names></name>, <name><surname>Brookland</surname><given-names>RK</given-names></name>, <etal/><article-title>The Eighth Edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging.</article-title><source>CA A Cancer J Clin</source><year>2017</year>;<volume>67</volume>:<fpage>93</fpage>–<lpage>9</lpage>.</mixed-citation>
    </ref>
    <ref id="R29">
      <label>[29]</label>
      <mixed-citation publication-type="book"><name><surname>Rubin</surname><given-names>DB</given-names></name>, editor. <source>Multiple imputation for nonresponse in surveys</source><publisher-loc>Hoboken, NJ, USA</publisher-loc>: <publisher-name>John Wiley &amp; Sons, Inc.</publisher-name>; <year>1987</year>.</mixed-citation>
    </ref>
    <ref id="R30">
      <label>[30]</label>
      <mixed-citation publication-type="journal"><name><surname>van Dijk</surname><given-names>LV</given-names></name>, <name><surname>Brouwer</surname><given-names>CL</given-names></name>, <name><surname>van der Schaaf</surname><given-names>A</given-names></name>, <name><surname>Burgerhof</surname><given-names>JGM</given-names></name>, <name><surname>Beukinga</surname><given-names>RJ</given-names></name>, <name><surname>Langendijk</surname><given-names>JA</given-names></name>, <etal/><article-title>CT image biomarkers to improve patient-specific prediction of radiation-induced xerostomia and sticky saliva.</article-title><source>Radiother Oncol</source><year>2017</year>;<volume>122</volume>:<fpage>185</fpage>–<lpage>91</lpage>.<pub-id pub-id-type="pmid">27459902</pub-id></mixed-citation>
    </ref>
    <ref id="R31">
      <label>[31]</label>
      <mixed-citation publication-type="journal"><name><surname>van Dijk</surname><given-names>Lv</given-names></name>, <name><surname>Thor</surname><given-names>M</given-names></name>, <name><surname>Steenbakkers</surname><given-names>RJHM</given-names></name>, <name><surname>Apte</surname><given-names>A</given-names></name>, <name><surname>Zhai</surname><given-names>TT</given-names></name>, <name><surname>Borra</surname><given-names>R</given-names></name>, <etal/><article-title>Parotid gland fat related Magnetic Resonance image biomarkers improve prediction of late radiation-induced xerostomia.</article-title><source>Radiother Oncol</source><year>2018</year>;<volume>128</volume>:<fpage>459</fpage>–<lpage>66</lpage>.<pub-id pub-id-type="pmid">29958772</pub-id></mixed-citation>
    </ref>
    <ref id="R32">
      <label>[32]</label>
      <mixed-citation publication-type="journal"><name><surname>Zwanenburg</surname><given-names>A</given-names></name>, <name><surname>Leger</surname><given-names>S</given-names></name>, <name><surname>Valliéres</surname><given-names>M</given-names></name>, <name><surname>Löck</surname><given-names>S</given-names></name>. <source>Image biomarker standardisation initiative - feature definitions</source><year>2016</year>. <comment>ArXiv: 161207003</comment>.</mixed-citation>
    </ref>
    <ref id="R33">
      <label>[33]</label>
      <mixed-citation publication-type="journal"><name><surname>Kowalski</surname><given-names>LP</given-names></name>, <name><surname>Carvalho</surname><given-names>AL</given-names></name>. <article-title>Natural history of untreated head and neck cancer.</article-title><source>Eur J Cancer</source><year>2000</year>;<volume>36</volume>:<fpage>1032</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="pmid">10885608</pub-id></mixed-citation>
    </ref>
    <ref id="R34">
      <label>[34]</label>
      <mixed-citation publication-type="journal"><name><surname>Coates</surname><given-names>A</given-names></name>, <name><surname>Porzsolt</surname><given-names>F</given-names></name>, <name><surname>Osoba</surname><given-names>D</given-names></name>. <article-title>Quality of life in oncology practice: prognostic value of EORTC QLQ-C30 scores in patients with advanced malignancy.</article-title><source>Eur J Cancer</source><year>1997</year>;<volume>33</volume>:<fpage>1025</fpage>–<lpage>30</lpage>.<pub-id pub-id-type="pmid">9376182</pub-id></mixed-citation>
    </ref>
    <ref id="R35">
      <label>[35]</label>
      <mixed-citation publication-type="journal"><name><surname>Datema</surname><given-names>FR</given-names></name>, <name><surname>Ferrier</surname><given-names>MB</given-names></name>, <name><surname>Vergouwe</surname><given-names>Y</given-names></name>, <name><surname>Moya</surname><given-names>A</given-names></name>, <name><surname>Molenaar</surname><given-names>J</given-names></name>, <name><surname>Piccirillo</surname><given-names>JF</given-names></name>, <etal/><article-title>Update and external validation of a head and neck cancer prognostic model.</article-title><source>Head Neck</source><year>2013</year>;<volume>35</volume>:<fpage>1232</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="pmid">22847987</pub-id></mixed-citation>
    </ref>
    <ref id="R36">
      <label>[36]</label>
      <mixed-citation publication-type="journal"><name><surname>Beesley</surname><given-names>LJ</given-names></name>, <name><surname>Hawkins</surname><given-names>PG</given-names></name>, <name><surname>Amlani</surname><given-names>LM</given-names></name>, <name><surname>Bellile</surname><given-names>EL</given-names></name>, <name><surname>Casper</surname><given-names>KA</given-names></name>, <name><surname>Chinn</surname><given-names>SB</given-names></name>, <etal/><article-title>Individualized survival prediction for patients with oropharyngeal cancer in the human papillomavirus era.</article-title><source>Cancer</source><year>2019</year>;<volume>125</volume>:<fpage>68</fpage>–<lpage>78</lpage>.<pub-id pub-id-type="pmid">30291798</pub-id></mixed-citation>
    </ref>
    <ref id="R37">
      <label>[37]</label>
      <mixed-citation publication-type="journal"><name><surname>Grégoire</surname><given-names>V</given-names></name>, <name><surname>Coche</surname><given-names>E</given-names></name>, <name><surname>Cosnard</surname><given-names>G</given-names></name>, <name><surname>Hamoir</surname><given-names>M</given-names></name>, <name><surname>Reychler</surname><given-names>H</given-names></name>. <article-title>Selection and delineation of lymph node target volumes in head and neck conformal radiotherapy. Proposal for standardizing terminology and procedure based on the surgical experience.</article-title><source>Radiother Oncol</source><year>2000</year>;<volume>56</volume>:<fpage>135</fpage>–<lpage>50</lpage>.<pub-id pub-id-type="pmid">10927132</pub-id></mixed-citation>
    </ref>
    <ref id="R38">
      <label>[38]</label>
      <mixed-citation publication-type="journal"><name><surname>Ger</surname><given-names>RB</given-names></name>, <name><surname>Zhou</surname><given-names>S</given-names></name>, <name><surname>Elgohari</surname><given-names>B</given-names></name>, <name><surname>Elhalawani</surname><given-names>H</given-names></name>, <name><surname>Mackin</surname><given-names>DM</given-names></name>, <name><surname>Meier</surname><given-names>JG</given-names></name>, <etal/><article-title>Radiomics features of the primary tumor fail to improve prediction of overall survival in large cohorts of CT- and PET-imaged head and neck cancer patients.</article-title><source>PLoS One</source><year>2019</year>;<volume>14</volume>:<fpage>1</fpage>–<lpage>13</lpage>.</mixed-citation>
    </ref>
    <ref id="R39">
      <label>[39]</label>
      <mixed-citation publication-type="journal"><name><surname>Ger</surname><given-names>RB</given-names></name>, <name><surname>Zhou</surname><given-names>S</given-names></name>, <name><surname>Chi</surname><given-names>PCM</given-names></name>, <name><surname>Lee</surname><given-names>HJ</given-names></name>, <name><surname>Layman</surname><given-names>RR</given-names></name>, <name><surname>Jones</surname><given-names>AK</given-names></name>, <etal/><article-title>Comprehensive investigation on controlling for CT imaging variabilities in radiomics studies.</article-title><source>Sci Rep</source><year>2018</year>;<volume>8</volume>:<fpage>1</fpage>–<lpage>14</lpage>.<pub-id pub-id-type="pmid">29311619</pub-id></mixed-citation>
    </ref>
    <ref id="R40">
      <label>[40]</label>
      <mixed-citation publication-type="journal"><name><surname>Ho</surname><given-names>AS</given-names></name>, <name><surname>Kraus</surname><given-names>DH</given-names></name>, <name><surname>Ganly</surname><given-names>I</given-names></name>, <name><surname>Lee</surname><given-names>NY</given-names></name>, <name><surname>Shah</surname><given-names>JP</given-names></name>, <name><surname>Morris</surname><given-names>LGT</given-names></name>. <article-title>Decision making in the management of recurrent head and neck cancer.</article-title><source>Head Neck</source><year>2014</year>;<volume>36</volume>:<fpage>144</fpage>–<lpage>51</lpage>.<pub-id pub-id-type="pmid">23471843</pub-id></mixed-citation>
    </ref>
  </ref-list>
</back>
<floats-group>
  <fig position="float" id="F1">
    <label>Fig. 1.</label>
    <caption>
      <title>Study overview.</title>
      <p id="P51"><italic toggle="yes">(A) Serial prediction model design.</italic> The ‘fundamental clinical model’ component is the core component as it is based data of &gt;4500 patients; the ‘predicted risk(%)’ can be refined with the ‘optional imaging component’, using radiomics features to improve the outcome risk prediction (‘refined Predicted Risk (%)’) to stratify patients in low-, intermediate-, and high-risk patients. The imaging component can be dynamically updated with future technical developments. (B) <italic toggle="yes">Datasets for clinical model training, validation, and external validation.</italic> Partial cases are patient that are missing at least one variable. Only complete cases were used for the validation of the models.</p>
    </caption>
    <graphic xlink:href="nihms-1864360-f0001" position="float"/>
  </fig>
  <fig position="float" id="F2">
    <label>Fig. 2.</label>
    <caption>
      <title>Patient stratification based on predicted mortality risk.</title>
      <p id="P52">Survival curves for low risk (in green; 2-year mortality risk&lt;5%), intermediate risk (in orange; risk≥5 and &lt;25%), and high risk (in blue; ≥25%) in training, validation, and two external validation cohort. Note: Follow-up time was truncated at 6 years for UMCG and 10 years for MDACC and PMH data. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)</p>
    </caption>
    <graphic xlink:href="nihms-1864360-f0002" position="float"/>
  </fig>
  <fig position="float" id="F3">
    <label>Fig. 3.</label>
    <caption>
      <title>Predicted overall survival risk based on clinical model versus <italic toggle="yes">AJCC</italic><sup><italic toggle="yes">8th</italic></sup> staging.</title>
      <p id="P53">Predicted 2-year mortality risk (y-axis) depicted per <italic toggle="yes">AJCC</italic><sup><italic toggle="yes">8th</italic></sup> stage group (left); percentages on x-axis are risks predicted based on staging alone. Survival curves show clear split with model-based risk stratification both in patients with low (right, top) and advanced <italic toggle="yes">AJCC</italic><sup><italic toggle="yes">8th</italic></sup> stage (right, bottom) patients. These figures are based on the MDACC data.</p>
    </caption>
    <graphic xlink:href="nihms-1864360-f0003" position="float"/>
  </fig>
  <table-wrap position="float" id="T1" orientation="landscape">
    <label>Table 1</label>
    <caption>
      <p id="P54">Demographics for training, independent validation, and two validation cohorts.</p>
    </caption>
    <table frame="hsides" rules="groups">
      <colgroup span="1">
        <col align="left" valign="middle" span="1"/>
        <col align="left" valign="middle" span="1"/>
        <col align="left" valign="middle" span="1"/>
        <col align="left" valign="middle" span="1"/>
        <col align="left" valign="middle" span="1"/>
        <col align="left" valign="middle" span="1"/>
        <col align="left" valign="middle" span="1"/>
        <col align="left" valign="middle" span="1"/>
        <col align="left" valign="middle" span="1"/>
        <col align="left" valign="middle" span="1"/>
      </colgroup>
      <thead>
        <tr>
          <th align="left" valign="top" rowspan="1" colspan="1"/>
          <th colspan="2" align="left" valign="top" rowspan="1">MDACC training</th>
          <th colspan="2" align="left" valign="top" rowspan="1">MDACC validation</th>
          <th colspan="2" align="left" valign="top" rowspan="1">UMCG validation</th>
          <th colspan="2" align="left" valign="top" rowspan="1">TCIA PMH validation</th>
          <th align="left" valign="top" rowspan="1" colspan="1">p-value</th>
        </tr>
      </thead>
      <tbody>
        <tr>
          <td align="left" valign="top" rowspan="1" colspan="1">
            <bold>N</bold>
          </td>
          <td colspan="2" align="left" valign="top" rowspan="1">2241</td>
          <td colspan="2" align="left" valign="top" rowspan="1">786</td>
          <td colspan="2" align="left" valign="top" rowspan="1">1087</td>
          <td colspan="2" align="left" valign="top" rowspan="1">497</td>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
        </tr>
        <tr>
          <td align="left" valign="top" rowspan="1" colspan="1">
            <bold>Age (mean (SD))</bold>
          </td>
          <td align="left" valign="top" rowspan="1" colspan="1">59.48</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(10.14)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">59.74</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(9.74)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">64.17</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(10.56)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">60.16</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(9.90)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">&lt;0.001</td>
        </tr>
        <tr>
          <td align="left" valign="top" rowspan="1" colspan="1">
            <bold>Sex (%)</bold>
          </td>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
        </tr>
        <tr>
          <td align="left" valign="top" rowspan="1" colspan="1"> Female</td>
          <td align="left" valign="top" rowspan="1" colspan="1">373</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(17)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">130</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(17)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">324</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(30)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">105</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(21)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">&lt;0.001</td>
        </tr>
        <tr>
          <td align="left" valign="top" rowspan="1" colspan="1"> Male</td>
          <td align="left" valign="top" rowspan="1" colspan="1">1868</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(83)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">656</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(83)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">763</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(70)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">392</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(79)</td>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
        </tr>
        <tr>
          <td align="left" valign="top" rowspan="1" colspan="1">
            <bold>T stage (%)</bold>
          </td>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
          <td align="left" valign="top" rowspan="1" colspan="1">&lt;0.001</td>
        </tr>
        <tr>
          <td align="left" valign="top" rowspan="1" colspan="1"> T0</td>
          <td align="left" valign="top" rowspan="1" colspan="1">53</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(2)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">17</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(2)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">2</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(0)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(0)</td>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
        </tr>
        <tr>
          <td align="left" valign="top" rowspan="1" colspan="1"> T1</td>
          <td align="left" valign="top" rowspan="1" colspan="1">507</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(23)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">178</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(23)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">196</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(18)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">90</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(18)</td>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
        </tr>
        <tr>
          <td align="left" valign="top" rowspan="1" colspan="1"> T2</td>
          <td align="left" valign="top" rowspan="1" colspan="1">788</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(35)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">288</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(37)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">262</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(24)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">162</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(33)</td>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
        </tr>
        <tr>
          <td align="left" valign="top" rowspan="1" colspan="1"> T3</td>
          <td align="left" valign="top" rowspan="1" colspan="1">453</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(20)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">162</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(21)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">251</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(23)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">146</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(29)</td>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
        </tr>
        <tr>
          <td align="left" valign="top" rowspan="1" colspan="1"> T4</td>
          <td align="left" valign="top" rowspan="1" colspan="1">414</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(18)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">136</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(17)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">376</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(35)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">99</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(20)</td>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
        </tr>
        <tr>
          <td align="left" valign="top" rowspan="1" colspan="1"> Tx</td>
          <td align="left" valign="top" rowspan="1" colspan="1">26</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(1)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">5</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(1)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(0)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(0)</td>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
        </tr>
        <tr>
          <td align="left" valign="top" rowspan="1" colspan="1">
            <bold>N stage (%)</bold>
          </td>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
          <td align="left" valign="top" rowspan="1" colspan="1">&lt;0.001</td>
        </tr>
        <tr>
          <td align="left" valign="top" rowspan="1" colspan="1"> N0</td>
          <td align="left" valign="top" rowspan="1" colspan="1">487</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(22)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">152</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(19)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">435</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(40)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">82</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(16)</td>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
        </tr>
        <tr>
          <td align="left" valign="top" rowspan="1" colspan="1"> N1</td>
          <td align="left" valign="top" rowspan="1" colspan="1">276</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(12)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">116</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(15)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">130</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(12)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">48</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(10)</td>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
        </tr>
        <tr>
          <td align="left" valign="top" rowspan="1" colspan="1"> N2a-b</td>
          <td align="left" valign="top" rowspan="1" colspan="1">1081</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(48)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">356</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(45)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">279</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(26)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">202</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(41)</td>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
        </tr>
        <tr>
          <td align="left" valign="top" rowspan="1" colspan="1"> N2c</td>
          <td align="left" valign="top" rowspan="1" colspan="1">318</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(14)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">141</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(18)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">202</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(19)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">123</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(25)</td>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
        </tr>
        <tr>
          <td align="left" valign="top" rowspan="1" colspan="1"> N3</td>
          <td align="left" valign="top" rowspan="1" colspan="1">79</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(4)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">21</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(3)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">37</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(3)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">42</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(8)</td>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
        </tr>
        <tr>
          <td align="left" valign="top" rowspan="1" colspan="1">
            <bold>HPV status (%)</bold>
          </td>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
          <td align="left" valign="top" rowspan="1" colspan="1">&lt;0.001</td>
        </tr>
        <tr>
          <td align="left" valign="top" rowspan="1" colspan="1"> Negative</td>
          <td align="left" valign="top" rowspan="1" colspan="1">617</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(28)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">288</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(37)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">912</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(84)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">142</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(29)</td>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
        </tr>
        <tr>
          <td align="left" valign="top" rowspan="1" colspan="1"> Positive</td>
          <td align="left" valign="top" rowspan="1" colspan="1">990</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(44)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">498</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(63)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">175</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(16)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">355</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(71)</td>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
        </tr>
        <tr>
          <td align="left" valign="top" rowspan="1" colspan="1"> Unknown</td>
          <td align="left" valign="top" rowspan="1" colspan="1">634</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(28)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(0)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(0)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(0)</td>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
        </tr>
        <tr>
          <td align="left" valign="top" rowspan="1" colspan="1">
            <bold>Site (%)</bold>
          </td>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
          <td align="left" valign="top" rowspan="1" colspan="1">&lt;0.001</td>
        </tr>
        <tr>
          <td align="left" valign="top" rowspan="1" colspan="1"> Oropharynx</td>
          <td align="left" valign="top" rowspan="1" colspan="1">1382</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(62)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">462</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(59)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">328</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(30)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">497</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(100)</td>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
        </tr>
        <tr>
          <td align="left" valign="top" rowspan="1" colspan="1"> Larynx</td>
          <td align="left" valign="top" rowspan="1" colspan="1">420</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(19)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">179</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(23)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">446</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(41)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(0)</td>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
        </tr>
        <tr>
          <td align="left" valign="top" rowspan="1" colspan="1"> Oral Cavity</td>
          <td align="left" valign="top" rowspan="1" colspan="1">314</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(14)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">95</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(12)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">263</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(24)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(0)</td>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
        </tr>
        <tr>
          <td align="left" valign="top" rowspan="1" colspan="1"> Hypopharynx</td>
          <td align="left" valign="top" rowspan="1" colspan="1">50</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(2)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">32</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(4)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">26</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(2)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(0)</td>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
        </tr>
        <tr>
          <td align="left" valign="top" rowspan="1" colspan="1"> Nasopharynx</td>
          <td align="left" valign="top" rowspan="1" colspan="1">22</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(1)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(0)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">23</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(2)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(0)</td>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
        </tr>
        <tr>
          <td align="left" valign="top" rowspan="1" colspan="1"> Unkown primary</td>
          <td align="left" valign="top" rowspan="1" colspan="1">53</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(2)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">18</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(2)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">1</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(0)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(0)</td>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
        </tr>
        <tr>
          <td align="left" valign="top" rowspan="1" colspan="1">
            <bold>AJCC</bold>
            <sup>
              <bold>8th</bold>
            </sup>
            <bold>stage (%)</bold>
          </td>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
          <td align="left" valign="top" rowspan="1" colspan="1">&lt;0.001</td>
        </tr>
        <tr>
          <td align="left" valign="top" rowspan="1" colspan="1"> I</td>
          <td align="left" valign="top" rowspan="1" colspan="1">605</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(27)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">271</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(34)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">159</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(15)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">156</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(31)</td>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
        </tr>
        <tr>
          <td align="left" valign="top" rowspan="1" colspan="1"> II</td>
          <td align="left" valign="top" rowspan="1" colspan="1">368</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(16)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">157</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(20)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">163</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(15)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">137</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(28)</td>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
        </tr>
        <tr>
          <td align="left" valign="top" rowspan="1" colspan="1"> III</td>
          <td align="left" valign="top" rowspan="1" colspan="1">349</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(16)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">143</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(18)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">247</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(23)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">106</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(21)</td>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
        </tr>
        <tr>
          <td align="left" valign="top" rowspan="1" colspan="1"> IVa</td>
          <td align="left" valign="top" rowspan="1" colspan="1">472</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(21)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">206</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(26)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">491</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(45)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">87</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(18)</td>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
        </tr>
        <tr>
          <td align="left" valign="top" rowspan="1" colspan="1"> IVb</td>
          <td align="left" valign="top" rowspan="1" colspan="1">29</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(1)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">9</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(1)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">27</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(2)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">11</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(2)</td>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
        </tr>
        <tr>
          <td align="left" valign="top" rowspan="1" colspan="1"> Unknown</td>
          <td align="left" valign="top" rowspan="1" colspan="1">418</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(19)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(0)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(0)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(0)</td>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
        </tr>
        <tr>
          <td align="left" valign="top" rowspan="1" colspan="1">
            <bold>Performance score (%)</bold>
          </td>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
          <td align="left" valign="top" rowspan="1" colspan="1">&lt;0.001</td>
        </tr>
        <tr>
          <td align="left" valign="top" rowspan="1" colspan="1"> 0</td>
          <td align="left" valign="top" rowspan="1" colspan="1">850</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(38)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">397</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(51)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">619</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(57)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">323</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(65)</td>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
        </tr>
        <tr>
          <td align="left" valign="top" rowspan="1" colspan="1"> 1</td>
          <td align="left" valign="top" rowspan="1" colspan="1">620</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(28)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">319</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(41)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">350</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(32)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">125</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(25)</td>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
        </tr>
        <tr>
          <td align="left" valign="top" rowspan="1" colspan="1"> &gt;2</td>
          <td align="left" valign="top" rowspan="1" colspan="1">181</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(8)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">70</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(9)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">118</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(11)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">49</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(10)</td>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
        </tr>
        <tr>
          <td align="left" valign="top" rowspan="1" colspan="1"> Unknown</td>
          <td align="left" valign="top" rowspan="1" colspan="1">590</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(26)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(0)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(0)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(0)</td>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
        </tr>
        <tr>
          <td align="left" valign="top" rowspan="1" colspan="1">
            <bold>Smoking status (%)</bold>
          </td>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
          <td align="left" valign="top" rowspan="1" colspan="1">&lt;0.001</td>
        </tr>
        <tr>
          <td align="left" valign="top" rowspan="1" colspan="1"> Never</td>
          <td align="left" valign="top" rowspan="1" colspan="1">773</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(34)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">301</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(38)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">175</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(16)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">144</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(29)</td>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
        </tr>
        <tr>
          <td align="left" valign="top" rowspan="1" colspan="1"> Former</td>
          <td align="left" valign="top" rowspan="1" colspan="1">998</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(45)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">360</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(46)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">457</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(42)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">198</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(40)</td>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
        </tr>
        <tr>
          <td align="left" valign="top" rowspan="1" colspan="1"> Current</td>
          <td align="left" valign="top" rowspan="1" colspan="1">453</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(20)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">125</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(16)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">427</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(39)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">155</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(31)</td>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
        </tr>
        <tr>
          <td align="left" valign="top" rowspan="1" colspan="1"> Unknown</td>
          <td align="left" valign="top" rowspan="1" colspan="1">17</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(1)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(0)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">28</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(3)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(0)</td>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
        </tr>
        <tr>
          <td align="left" valign="top" rowspan="1" colspan="1">
            <bold>Pack years (mean (SD))</bold>
          </td>
          <td align="left" valign="top" rowspan="1" colspan="1">22.03</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(33.69)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">20.01</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(28.19)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">30.77</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(23.90)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">24.35</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(24.67)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">&lt;0.001</td>
        </tr>
        <tr>
          <td align="left" valign="top" rowspan="1" colspan="1">
            <bold>Chemotherapy (%)</bold>
          </td>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
          <td align="left" valign="top" rowspan="1" colspan="1">&lt;0.001</td>
        </tr>
        <tr>
          <td align="left" valign="top" rowspan="1" colspan="1"> None</td>
          <td align="left" valign="top" rowspan="1" colspan="1">446</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(20)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">115</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(15)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">696</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(64)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">254</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(51)</td>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
        </tr>
        <tr>
          <td align="left" valign="top" rowspan="1" colspan="1"> Concurrent</td>
          <td align="left" valign="top" rowspan="1" colspan="1">1060</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(47)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">410</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(52)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">389</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(36)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">243</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(49)</td>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
        </tr>
        <tr>
          <td align="left" valign="top" rowspan="1" colspan="1"> Induction</td>
          <td align="left" valign="top" rowspan="1" colspan="1">218</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(10)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">100</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(13)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">1</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(0)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(0)</td>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
        </tr>
        <tr>
          <td align="left" valign="top" rowspan="1" colspan="1"> Induction + concurrent</td>
          <td align="left" valign="top" rowspan="1" colspan="1">480</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(21)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">161</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(20)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">1</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(0)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(0)</td>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
        </tr>
        <tr>
          <td align="left" valign="top" rowspan="1" colspan="1"> Unknown</td>
          <td align="left" valign="top" rowspan="1" colspan="1">37</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(2)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(0)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(0)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(0)</td>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
        </tr>
        <tr>
          <td align="left" valign="top" rowspan="1" colspan="1">
            <bold>Technique (%)</bold>
          </td>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
          <td align="left" valign="top" rowspan="1" colspan="1">&lt;0.001</td>
        </tr>
        <tr>
          <td align="left" valign="top" rowspan="1" colspan="1"> 3DCRT</td>
          <td align="left" valign="top" rowspan="1" colspan="1">211</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(9)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">9</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(1)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">14</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(1)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(0)</td>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
        </tr>
        <tr>
          <td align="left" valign="top" rowspan="1" colspan="1"> IMRT</td>
          <td align="left" valign="top" rowspan="1" colspan="1">1496</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(67)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">450</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(57)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">517</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(48)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">497</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(100)</td>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
        </tr>
        <tr>
          <td align="left" valign="top" rowspan="1" colspan="1"> VMAT</td>
          <td align="left" valign="top" rowspan="1" colspan="1">466</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(21)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">292</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(37)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">401</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(37)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(0)</td>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
        </tr>
        <tr>
          <td align="left" valign="top" rowspan="1" colspan="1"> IMPT</td>
          <td align="left" valign="top" rowspan="1" colspan="1">68</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(3)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">35</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(4)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">111</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(10)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(0)</td>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
        </tr>
        <tr>
          <td align="left" valign="top" rowspan="1" colspan="1"> Unknown</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(0)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(0)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">44</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(4)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(0)</td>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
        </tr>
        <tr>
          <td align="left" valign="top" rowspan="1" colspan="1">
            <bold>Radiotherapy type (%)</bold>
          </td>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
          <td align="left" valign="top" rowspan="1" colspan="1">&lt;0.001</td>
        </tr>
        <tr>
          <td align="left" valign="top" rowspan="1" colspan="1"> Primary</td>
          <td align="left" valign="top" rowspan="1" colspan="1">1727</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(77)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">644</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(82)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">852</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(78)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">497</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(100)</td>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
        </tr>
        <tr>
          <td align="left" valign="top" rowspan="1" colspan="1"> Post-operative</td>
          <td align="left" valign="top" rowspan="1" colspan="1">251</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(11)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">40</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(5)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">230</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(21)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(0)</td>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
        </tr>
        <tr>
          <td align="left" valign="top" rowspan="1" colspan="1"> Unknown</td>
          <td align="left" valign="top" rowspan="1" colspan="1">263</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(12)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">102</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(13)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">5</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(0)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(0)</td>
          <td align="left" valign="top" rowspan="1" colspan="1"/>
        </tr>
        <tr>
          <td align="left" valign="top" rowspan="1" colspan="1">
            <bold>Mortality events (%)</bold>
          </td>
          <td align="left" valign="top" rowspan="1" colspan="1">635</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(28)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">148</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(19)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">402</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(37)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">206</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(41)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">&lt;0.001</td>
        </tr>
        <tr>
          <td align="left" valign="top" rowspan="1" colspan="1">
            <bold>Local failure events (%)</bold>
          </td>
          <td align="left" valign="top" rowspan="1" colspan="1">233</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(10)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">70</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(9)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">149</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(14)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">46</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(9)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">&lt;0.001</td>
        </tr>
        <tr>
          <td align="left" valign="top" rowspan="1" colspan="1">
            <bold>Regional failure events (%)</bold>
          </td>
          <td align="left" valign="top" rowspan="1" colspan="1">182</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(8)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">48</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(6)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">105</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(10)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">31</td>
          <td align="left" valign="top" rowspan="1" colspan="1">(6)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0.005</td>
        </tr>
      </tbody>
    </table>
    <table-wrap-foot>
      <fn id="TFN1">
        <p id="P55">Abbreviations: SD: standard deviation; HPV, human papilloma virus; 3DCRT, three-dimensional conformal radiotherapy; IMRT, intensity-modulated radiotherapy; VMAT, volumetric-modulated arc therapy; IMPT, intensity-modulated proton therapy.</p>
      </fn>
    </table-wrap-foot>
  </table-wrap>
  <table-wrap position="float" id="T2" orientation="landscape">
    <label>Table 2</label>
    <caption>
      <p id="P56">Clinical model parameters and c-index model performance.</p>
    </caption>
    <table frame="hsides" rules="groups">
      <colgroup span="1">
        <col align="left" valign="middle" span="1"/>
        <col align="left" valign="middle" span="1"/>
        <col align="left" valign="middle" span="1"/>
        <col align="left" valign="middle" span="1"/>
        <col align="left" valign="middle" span="1"/>
      </colgroup>
      <thead>
        <tr>
          <th colspan="5" align="left" valign="middle" rowspan="1">Overall survival (OS)<hr/></th>
        </tr>
        <tr>
          <th align="left" valign="middle" rowspan="1" colspan="1">Variables</th>
          <th align="left" valign="middle" rowspan="1" colspan="1">Category</th>
          <th align="left" valign="middle" rowspan="1" colspan="1">Coefficients</th>
          <th align="left" valign="middle" rowspan="1" colspan="1">Hazard ratio</th>
          <th align="left" valign="middle" rowspan="1" colspan="1">p value</th>
        </tr>
      </thead>
      <tbody>
        <tr>
          <td rowspan="3" align="left" valign="top" colspan="1">Performance score</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0</td>
          <td align="left" valign="top" rowspan="1" colspan="1">1</td>
          <td align="left" valign="top" rowspan="1" colspan="1">ref</td>
        </tr>
        <tr>
          <td align="left" valign="top" rowspan="1" colspan="1">1</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0.469</td>
          <td align="left" valign="top" rowspan="1" colspan="1">1.6 (1.28–1.99)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">&lt;0.0001</td>
        </tr>
        <tr>
          <td align="left" valign="top" rowspan="1" colspan="1">≥2</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0.781</td>
          <td align="left" valign="top" rowspan="1" colspan="1">2.18 (1.51–3.16)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0.0001</td>
        </tr>
        <tr>
          <td rowspan="5" align="left" valign="top" colspan="1"><italic toggle="yes">AJCC</italic><sup><italic toggle="yes">8th</italic></sup> stage</td>
          <td align="left" valign="top" rowspan="1" colspan="1">I</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0</td>
          <td align="left" valign="top" rowspan="1" colspan="1">1</td>
          <td align="left" valign="top" rowspan="1" colspan="1">ref</td>
        </tr>
        <tr>
          <td align="left" valign="top" rowspan="1" colspan="1">II</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0.117</td>
          <td align="left" valign="top" rowspan="1" colspan="1">1.12 (0.76–1.65)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0.5545</td>
        </tr>
        <tr>
          <td align="left" valign="top" rowspan="1" colspan="1">III</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0.679</td>
          <td align="left" valign="top" rowspan="1" colspan="1">1.97 (1.42–2.74)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0.0001</td>
        </tr>
        <tr>
          <td align="left" valign="top" rowspan="1" colspan="1">IVa</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0.793</td>
          <td align="left" valign="top" rowspan="1" colspan="1">2.21 (1.66–2.94)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">&lt;0.0001</td>
        </tr>
        <tr>
          <td align="left" valign="top" rowspan="1" colspan="1">IVb</td>
          <td align="left" valign="top" rowspan="1" colspan="1">1.509</td>
          <td align="left" valign="top" rowspan="1" colspan="1">4.52 (2.79–7.33)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">&lt;0.0001</td>
        </tr>
        <tr>
          <td rowspan="4" align="left" valign="top" colspan="1">Pack years</td>
          <td align="left" valign="top" rowspan="1" colspan="1">≤5</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0</td>
          <td align="left" valign="top" rowspan="1" colspan="1">1</td>
          <td align="left" valign="top" rowspan="1" colspan="1">ref</td>
        </tr>
        <tr>
          <td align="left" valign="top" rowspan="1" colspan="1">5–25</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0.267</td>
          <td align="left" valign="top" rowspan="1" colspan="1">1.31 (1.01–1.7)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0.0459</td>
        </tr>
        <tr>
          <td align="left" valign="top" rowspan="1" colspan="1">26–50</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0.499</td>
          <td align="left" valign="top" rowspan="1" colspan="1">1.65 (1.3–2.08)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">&lt;0.0001</td>
        </tr>
        <tr>
          <td align="left" valign="top" rowspan="1" colspan="1">&gt;50</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0.867</td>
          <td align="left" valign="top" rowspan="1" colspan="1">2.38 (1.78–3.17)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">&lt;0.0001</td>
        </tr>
        <tr>
          <td rowspan="4" align="left" valign="top" colspan="1">Age</td>
          <td align="left" valign="top" rowspan="1" colspan="1">≤55</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0</td>
          <td align="left" valign="top" rowspan="1" colspan="1">1</td>
          <td align="left" valign="top" rowspan="1" colspan="1">ref</td>
        </tr>
        <tr>
          <td align="left" valign="top" rowspan="1" colspan="1">56–65</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0.085</td>
          <td align="left" valign="top" rowspan="1" colspan="1">1.09 (0.89–1.33)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0.4113</td>
        </tr>
        <tr>
          <td align="left" valign="top" rowspan="1" colspan="1">65–75</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0.400</td>
          <td align="left" valign="top" rowspan="1" colspan="1">1.49 (1.2–1.85)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0.0003</td>
        </tr>
        <tr>
          <td align="left" valign="top" rowspan="1" colspan="1">&gt;75</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0.753</td>
          <td align="left" valign="top" rowspan="1" colspan="1">2.12 (1.56–2.89)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">&lt;0.0001</td>
        </tr>
      </tbody>
      <tbody>
        <tr>
          <th colspan="5" align="left" valign="middle" rowspan="1">Local control (LC)<hr/></th>
        </tr>
        <tr>
          <th align="left" valign="middle" rowspan="1" colspan="1">Variables</th>
          <th align="left" valign="middle" rowspan="1" colspan="1">Category</th>
          <th align="left" valign="middle" rowspan="1" colspan="1">Coefficients</th>
          <th align="left" valign="middle" rowspan="1" colspan="1">Hazard ratio</th>
          <th align="left" valign="middle" rowspan="1" colspan="1">p value</th>
        </tr>
        <tr>
          <th colspan="5" align="left" valign="middle" rowspan="1">
            <hr/>
          </th>
        </tr>
        <tr>
          <td rowspan="4" align="left" valign="top" colspan="1">T stage</td>
          <td align="left" valign="top" rowspan="1" colspan="1">T1</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0</td>
          <td align="left" valign="top" rowspan="1" colspan="1">1</td>
          <td align="left" valign="top" rowspan="1" colspan="1">ref</td>
        </tr>
        <tr>
          <td align="left" valign="top" rowspan="1" colspan="1">T2</td>
          <td align="left" valign="top" rowspan="1" colspan="1">1.432</td>
          <td align="left" valign="top" rowspan="1" colspan="1">4.19 (2.19–8.03)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">&lt;0.0001</td>
        </tr>
        <tr>
          <td align="left" valign="top" rowspan="1" colspan="1">T3</td>
          <td align="left" valign="top" rowspan="1" colspan="1">1.473</td>
          <td align="left" valign="top" rowspan="1" colspan="1">4.36 (2.22–8.58)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">&lt;0.0001</td>
        </tr>
        <tr>
          <td align="left" valign="top" rowspan="1" colspan="1">T4</td>
          <td align="left" valign="top" rowspan="1" colspan="1">1.613</td>
          <td align="left" valign="top" rowspan="1" colspan="1">5.02 (2.56–9.83)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">&lt;0.0001</td>
        </tr>
        <tr>
          <td align="left" valign="top" rowspan="1" colspan="1">HPV status</td>
          <td align="left" valign="top" rowspan="1" colspan="1">positive = 1</td>
          <td align="left" valign="top" rowspan="1" colspan="1">−0.694</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0.5 (0.34–0.73)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0.0003</td>
        </tr>
        <tr>
          <td rowspan="3" align="left" valign="top" colspan="1">Performance score</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0</td>
          <td align="left" valign="top" rowspan="1" colspan="1">1</td>
          <td align="left" valign="top" rowspan="1" colspan="1">ref</td>
        </tr>
        <tr>
          <td align="left" valign="top" rowspan="1" colspan="1">1</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0.421</td>
          <td align="left" valign="top" rowspan="1" colspan="1">1.52 (1.05–2.22)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0.0276</td>
        </tr>
        <tr>
          <td align="left" valign="top" rowspan="1" colspan="1">≥2</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0.801</td>
          <td align="left" valign="top" rowspan="1" colspan="1">2.23 (1.38–3.59)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0.0010</td>
        </tr>
        <tr>
          <td rowspan="4" align="left" valign="top" colspan="1">Pack years</td>
          <td align="left" valign="top" rowspan="1" colspan="1">≤5</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0</td>
          <td align="left" valign="top" rowspan="1" colspan="1">1</td>
          <td align="left" valign="top" rowspan="1" colspan="1">ref</td>
        </tr>
        <tr>
          <td align="left" valign="top" rowspan="1" colspan="1">5–25</td>
          <td align="left" valign="top" rowspan="1" colspan="1">−0.039</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0.96 (0.58–1.6)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0.8807</td>
        </tr>
        <tr>
          <td align="left" valign="top" rowspan="1" colspan="1">26–50</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0.294</td>
          <td align="left" valign="top" rowspan="1" colspan="1">1.34 (0.87–2.08)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0.1858</td>
        </tr>
        <tr>
          <td align="left" valign="top" rowspan="1" colspan="1">&gt;50</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0.496</td>
          <td align="left" valign="top" rowspan="1" colspan="1">1.64 (1.02–2.64)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0.0403</td>
        </tr>
      </tbody>
      <tbody>
        <tr>
          <th colspan="5" align="left" valign="middle" rowspan="1">Regional control (RC)<hr/></th>
        </tr>
        <tr>
          <th align="left" valign="middle" rowspan="1" colspan="1">Variables</th>
          <th align="left" valign="middle" rowspan="1" colspan="1">Category</th>
          <th align="left" valign="middle" rowspan="1" colspan="1">Coefficients</th>
          <th align="left" valign="middle" rowspan="1" colspan="1">Hazard ratio</th>
          <th align="left" valign="middle" rowspan="1" colspan="1">p value</th>
        </tr>
        <tr>
          <th colspan="5" align="left" valign="middle" rowspan="1">
            <hr/>
          </th>
        </tr>
        <tr>
          <td rowspan="5" align="left" valign="top" colspan="1">AJCC8th stage</td>
          <td align="left" valign="top" rowspan="1" colspan="1">I</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0</td>
          <td align="left" valign="top" rowspan="1" colspan="1">1</td>
          <td align="left" valign="top" rowspan="1" colspan="1">ref</td>
        </tr>
        <tr>
          <td align="left" valign="top" rowspan="1" colspan="1">II</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0.442</td>
          <td align="left" valign="top" rowspan="1" colspan="1">1.56 (0.7–3.46)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0.2774</td>
        </tr>
        <tr>
          <td align="left" valign="top" rowspan="1" colspan="1">III</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0.984</td>
          <td align="left" valign="top" rowspan="1" colspan="1">2.68 (1.28–5.59)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0.0089</td>
        </tr>
        <tr>
          <td align="left" valign="top" rowspan="1" colspan="1">IVa</td>
          <td align="left" valign="top" rowspan="1" colspan="1">1.567</td>
          <td align="left" valign="top" rowspan="1" colspan="1">4.79 (2.34–9.81)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">&lt;0.0001</td>
        </tr>
        <tr>
          <td align="left" valign="top" rowspan="1" colspan="1">IVb</td>
          <td align="left" valign="top" rowspan="1" colspan="1">2.565</td>
          <td align="left" valign="top" rowspan="1" colspan="1">13 (4.76–35.55)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">&lt;0.0001</td>
        </tr>
        <tr>
          <td rowspan="3" align="left" valign="top" colspan="1">Performance score</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0</td>
          <td align="left" valign="top" rowspan="1" colspan="1">1</td>
          <td align="left" valign="top" rowspan="1" colspan="1">ref</td>
        </tr>
        <tr>
          <td align="left" valign="top" rowspan="1" colspan="1">1</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0.573</td>
          <td align="left" valign="top" rowspan="1" colspan="1">1.77 (1.15–2.73)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0.0093</td>
        </tr>
        <tr>
          <td align="left" valign="top" rowspan="1" colspan="1">≥2</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0.793</td>
          <td align="left" valign="top" rowspan="1" colspan="1">2.21 (1.27–3.84)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0.0049</td>
        </tr>
        <tr>
          <td rowspan="6" align="left" valign="top" colspan="1">Tumour site</td>
          <td align="left" valign="top" rowspan="1" colspan="1">Hypopharynx</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0</td>
          <td align="left" valign="top" rowspan="1" colspan="1">1</td>
          <td align="left" valign="top" rowspan="1" colspan="1">ref</td>
        </tr>
        <tr>
          <td align="left" valign="top" rowspan="1" colspan="1">Larynx</td>
          <td align="left" valign="top" rowspan="1" colspan="1">−0.118</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0.89 (0.45–1.75)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0.7343</td>
        </tr>
        <tr>
          <td align="left" valign="top" rowspan="1" colspan="1">Oropharynx</td>
          <td align="left" valign="top" rowspan="1" colspan="1">−0.648</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0.52 (0.25–1.11)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0.0898</td>
        </tr>
        <tr>
          <td align="left" valign="top" rowspan="1" colspan="1">Oral cavity</td>
          <td align="left" valign="top" rowspan="1" colspan="1">−0.853</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0.43 (0.21–0.88)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0.0203</td>
        </tr>
        <tr>
          <td align="left" valign="top" rowspan="1" colspan="1">Unknown Prim</td>
          <td align="left" valign="top" rowspan="1" colspan="1">−1.140</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0.32 (0.07–1.51)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0.1493</td>
        </tr>
        <tr>
          <td align="left" valign="top" rowspan="1" colspan="1">Nasopharynx</td>
          <td align="left" valign="top" rowspan="1" colspan="1">−4.995</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0.01 (0–21498.48)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0.9932</td>
        </tr>
      </tbody>
      <tbody>
        <tr>
          <th colspan="5" align="left" valign="middle" rowspan="1">Model performance (c-index [95%CI])<hr/></th>
        </tr>
        <tr>
          <th align="left" valign="top" rowspan="1" colspan="1"/>
          <th align="left" valign="top" rowspan="1" colspan="1">MDACC Training</th>
          <th align="left" valign="top" rowspan="1" colspan="1">MDACC validation</th>
          <th align="left" valign="top" rowspan="1" colspan="1">UMCG external validation 1</th>
          <th align="left" valign="top" rowspan="1" colspan="1">MGH external validation 2</th>
        </tr>
        <tr>
          <th colspan="5" align="left" valign="middle" rowspan="1">
            <hr/>
          </th>
        </tr>
        <tr>
          <td align="left" valign="top" rowspan="1" colspan="1">Overall Survival (OS)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0.72 [0.66–0.78]</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0.76 [0.68–0.83]</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0.73 [0.68–0.78]</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0.75 [0.69–0.81]</td>
        </tr>
        <tr>
          <td align="left" valign="top" rowspan="1" colspan="1">Local control (LC)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0.74 [0.67–0.82]</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0.71 [0.58–0.84]</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0.70 [0.62–0.77]</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0.75 [0.61–0.90]</td>
        </tr>
        <tr>
          <td align="left" valign="top" rowspan="1" colspan="1">Regional control (RC)</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0.74 [0.64–0.83]</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0.73 [0.57–0.89]</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0.7 [0.62–0.78]</td>
          <td align="left" valign="top" rowspan="1" colspan="1">0.74 [0.56–0.91]</td>
        </tr>
      </tbody>
    </table>
    <table-wrap-foot>
      <fn id="TFN2">
        <p id="P57">Abbreviations: HPV, human papilloma virus; CI, confidence interval.</p>
      </fn>
    </table-wrap-foot>
  </table-wrap>
</floats-group>
